fluorouracil
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | FLUOROURACIL | — | 2016-07-29 | fda.gov ↗ |
| Approved | US (FDA) | FLUOROURACIL | — | 1962-04-25 | fda.gov ↗ |
Trials 1,489 · started per year
Also used as a comparator or background therapy in 1,341 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT07328087 Background | Feb 2026 → Dec 2030 expected | colorectal cancer | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT06011772 Background | Dec 2023 → Feb 2026 overdue | colorectal cancer | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05590117 Comparator | Oct 2022 → Oct 2023 | colorectal cancer, mucositis, peripheral neuropathy | Tanta University | Unknown | No outcome recorded |
| Phase 0 | NCT05108428 Background | Dec 2021 → Oct 2023 overdue | rectum adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02724202 Background | Feb 2018 → Jan 2020 | metastasis from malignant tumor of colon | Baylor Research Institute | Terminated | No outcome recorded |
| Phase 0 | NCT02019355 Background | Oct 2013 → Mar 2015 | actinic keratosis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT01858025 Background | Jul 2013 → Jul 2017 | anal canal carcinoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1183 trials | ||||||
| Phase 1 | NCT07700420 Background | Oct 2026 → Oct 2027 expected | esophageal cancer, gastroesophageal cancer | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07543471 Background | Jun 2026 → Jun 2027 expected | colorectal cancer | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07671339 Background | Jun 2026 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07619313 Background | Jun 2026 → Jun 2027 expected | cholangiocarcinoma, pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07532902 Background | Apr 2026 → Apr 2029 expected | diffused pleural mesothelioma, gastroesophageal cancer, urothelial carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Show all 183 trials opens the full record — a long page | ||||||
| Phase 1/2121 trials | ||||||
| Phase 1/2 | NCT07705919 Background | Sep 2026 → Dec 2027 expected | pancreatic ductal adenocarcinoma | Ohio State University Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07678593 Background | Sep 2026 → Nov 2027 expected | pancreatic ductal adenocarcinoma | Genfleet Therapeutics (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07683403 Comparator | Jun 2026 → Jun 2028 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07680569 Background | Jun 2026 → Dec 2027 expected | gastroesophageal junction adenocarcinoma | Kaohsiung Medical University Chung-Ho Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07456852 Background | Apr 2026 → Apr 2028 expected | digestive system cancer | Mayo Clinic | Recruiting | No outcome recorded |
| Show all 121 trials opens the full record — a long page | ||||||
| Phase 2552 trials | ||||||
| Phase 2 | NCT07625930 Background | Jan 2027 → Apr 2029 expected | gastroesophageal adenocarcinoma | McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07059611 Background | Sep 2026 → Nov 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Abramson Cancer Center at Penn Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07359456 Background | Aug 2026 → Aug 2029 expected | colorectal cancer | UNICANCER | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07662031 Background | Aug 2026 → Aug 2030 expected | colorectal cancer | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07622017 Background | Jul 2026 → Jan 2029 expected | rectal cancer | Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting | No outcome recorded |
| Show all 552 trials opens the full record — a long page | ||||||
| Phase 2/353 trials | ||||||
| Phase 2/3 | NCT07437287 Background | Jul 2026 → Apr 2030 expected | biliary tract cancer | UNICANCER | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07585279 Background | May 2026 → Feb 2031 expected | colorectal cancer | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07490301 Background | Apr 2026 → Jun 2031 expected | pancreatic ductal adenocarcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07332533 Background | Dec 2025 → Jun 2032 expected | carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06841679 Background | Aug 2025 → Sep 2030 expected | gastroesophageal adenocarcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06959693 Background | Jun 2025 → Sep 2028 expected | colorectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06662877 Comparator | Nov 2024 → Sep 2029 expected | biliary tract cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06079346 Comparator | May 2024 → Jun 2026 overdue | pancreatic ductal adenocarcinoma | Oncotelic Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06280495 Background | Feb 2024 → Dec 2026 expected | metastasis from malignant tumor of colon | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05945901 Comparator | Aug 2023 → Dec 2025 overdue | colorectal cancer | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05381597 Comparator | Oct 2022 → Jun 2027 expected | skin squamous cell carcinoma in situ, superficial multifocal basal cell carcinoma | Boston University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05484024 Background | Aug 2022 → Jul 2028 expected | rectal cancer | Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06509880 Comparator | Jul 2022 → Jul 2023 | — | MIPO Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT05174169 Comparator | Jul 2022 → Mar 2029 expected | malignant colon neoplasm | NRG Oncology | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05433597 Comparator | Jul 2022 → Jul 2024 overdue | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05213312 Background | Jun → Nov 2022 | esophageal squamous cell carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05065957 Comparator | Mar 2022 → Jul 2026 overdue | biliary tract cancer | InnoPharmax Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05513924 Comparator | Mar → Nov 2022 | vitiligo | South Valley University | Completed | No outcome recorded |
| Phase 2/3 | NCT05141721 Background | Feb 2022 → Mar 2027 expected | colorectal neoplasm | Seattle Project Corporation | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04037241 Background | Nov 2021 → Jan 2022 | malignant pancreatic neoplasm | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05125055 Comparator | Oct 2021 → Sep 2024 overdue | oral cavity squamous cell carcinoma | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03696004 Comparator | Dec 2018 → Jun 2019 | breast cancer | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03686254 Comparator | Jul 2018 → Oct 2023 | colorectal cancer | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03607656 Background | Jun 2018 → Oct 2022 | gastric cancer | Shanghai University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT03414983 Background | Feb 2018 → Feb 2021 | colorectal cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2/3 | NCT03130790 Comparator | Aug 2017 → Dec 2018 | gastric cancer | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT02661971 Background | Jun 2016 → Dec 2021 | gastric cancer, gastroesophageal cancer | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 2/3 | NCT02581462 Background | Jun 2016 → Jul 2020 | gastric cancer, gastroesophageal junction adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 2/3 | NCT03031444 Comparator | Jan 2016 → Dec 2020 | colorectal cancer, metastatic neoplasm | Peking University Cancer Hospital & Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT01404156 Comparator | Sep 2015 → Aug 2023 | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Dr. Gordon Buduhan | Completed | No outcome recorded |
| Phase 2/3 | NCT02527772 Comparator | Sep 2015 → Sep 2017 | hepatocellular carcinoma | Guangxi Medical University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02534337 Comparator | Sep 2015 → Sep 2017 | hepatocellular carcinoma | Guangxi Medical University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02415699 Background | Aug 2015 → Jul 2017 | colorectal cancer | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02590367 Background | Aug 2015 → Oct 2017 | peripheral neuropathy | Jiangsu Province Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 2/3 | NCT02510118 Background | Jun 2015 → Jun 2016 | colon carcinoma | Nanjing NingQi Medicine Science and Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT02494973 Comparator | May 2015 → Mar 2024 | colorectal cancer | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 2/3 | NCT02767375 Comparator | Feb 2015 → Dec 2017 | hepatocellular carcinoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT02135042 Comparator | Apr 2014 → Feb 2027 expected | Epstein-Barr virus infection, nasopharyngeal carcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01829178 Background | Aug 2013 → Sep 2014 | cisplatin toxicity, gastroesophageal adenocarcinoma | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01646554 Background | Dec 2012 → Dec 2015 | metastasis from malignant tumor of colon | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01704690 Comparator | Aug 2012 → Mar 2017 | esophageal cancer | Peking University | Terminated | No outcome recorded |
| Phase 2/3 | NCT01523431 Background | Mar 2012 → Nov 2015 | colorectal cancer | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02442362 Comparator | Jan 2012 → Jan 2014 | gastric cancer | The First People's Hospital of Changzhou | Completed | No outcome recorded |
| Phase 2/3 | NCT01433562 Background | Aug 2011 → Nov 2012 | breast cancer | Dexa Medica Group | Completed | No outcome recorded |
| Phase 2/3 | NCT03428529 Comparator | Jan 2011 → Oct 2016 | rectal cancer | Brazilian National Cancer Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT01206218 Comparator | Oct 2010 → Oct 2012 | gastric cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 2/3 | NCT01211210 Comparator | Jun 2010 → Jun 2017 | rectal cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00952029 Background | Mar 2010 → Dec 2015 | colorectal cancer | Federation Francophone de Cancerologie Digestive | Completed | No outcome recorded |
| Phase 2/3 | NCT01204437 Comparator | Mar 2009 → Jan 2014 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2/3 | NCT01249352 Background | Jan 2009 → Nov 2013 | adenocarcinoma, esophageal cancer | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 2/3 | NCT00384176 Background | Aug 2006 → Nov 2009 | colorectal cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2/3 | NCT00284258 Comparator | Jan 2006 → Jul 2010 | colorectal cancer | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT00785421 Comparator | Apr 2004 → Jan 2009 | pancreatic adenocarcinoma | CONKO-Studiengruppe | Completed | No outcome recorded |
| Phase 3353 trials | ||||||
| Phase 3 | NCT07271355 Background | Jul 2026 → Feb 2031 expected | appendix carcinoma, peritoneal carcinomatosis | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07676162 Background | Jul 2026 → Sep 2029 expected | colorectal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07595913 Comparator | Jul 2026 → Jun 2028 expected | neuroendocrine carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07702032 Background | Jul 2026 → Jul 2029 expected | colorectal cancer | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT07582315 Comparator | Jul 2026 → Dec 2028 expected | biliary tract cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Show all 353 trials opens the full record — a long page | ||||||
| Phase 431 trials | ||||||
| Phase 4 | NCT07094893 Background | Apr 2026 → Mar 2028 expected | colorectal cancer | Gruppo Oncologico del Nord-Ovest | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07020468 Background | May → Jul 2025 overdue | colorectal cancer | Affiliated Cancer Hospital of Shantou University Medical College | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06499415 Comparator | Sep 2024 → Mar 2029 expected | actinic keratosis | Maastricht University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06368063 Comparator | May 2024 → Mar 2026 overdue | pancreas disorder | Xi'an Jiaotong University | Recruiting | No outcome recorded |
| Phase 4 | NCT06269445 Background | Jan 2024 → Feb 2025 | colorectal cancer | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05008887 Comparator | Sep 2022 → Mar 2023 | vitiligo | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT05124002 Background | Aug 2022 → Apr 2026 | intrahepatic cholangiocarcinoma | Beijing Tsinghua Chang Gung Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04875026 Background | Feb 2021 → Jan 2022 | actinic keratosis | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT04747951 Background | Oct 2020 → Oct 2023 | rectal cancer | State Scientific Centre of Coloproctology, Russian Federation | Unknown | No outcome recorded |
| Phase 4 | NCT04810585 Background | Apr 2020 → Oct 2025 | colorectal cancer | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT03037736 Comparator | Mar 2020 | conjunctival pterygium | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 4 | NCT03909646 Comparator | May 2019 → Mar 2022 | Bowen disease of the skin | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03645187 Comparator | Aug 2018 → Aug 2025 | colon carcinoma | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT02860429 Background | Sep 2016 → Sep 2017 | digestive system neoplasm | Xiaonan Cui | Unknown | No outcome recorded |
| Phase 4 | NCT02688803 Comparator | Aug 2016 → Oct 2017 | breast cancer | Ottawa Hospital Research Institute | Terminated | No outcome recorded |
| Phase 4 | NCT03904381 Comparator | Jan 2016 → Jan 2024 | open-angle glaucoma | Wroclaw Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02366819 Background | Dec 2014 → Jun 2026 | esophageal adenocarcinoma, gastric adenocarcinoma | University of Chicago | Suspended | No outcome recorded |
| Phase 4 | NCT02281682 Comparator | Nov 2014 → Jul 2018 | actinic keratosis | Maastricht University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02155439 Comparator | May 2014 → Dec 2017 | keloid | Tampere University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02015650 Comparator | Apr 2014 → Apr 2016 | head and neck squamous cell carcinoma | Medical University Innsbruck | Terminated | No outcome recorded |
| Phase 4 | NCT01972490 Background | Oct 2013 → Dec 2017 | colorectal neoplasm | Xu jianmin | Completed | No outcome recorded |
| Phase 4 | NCT01849380 Comparator | Jun → Oct 2013 | breast cancer | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT03084809 Background | May 2012 → Sep 2014 | colorectal cancer | China Meitan General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01501487 Comparator | Oct 2011 → Feb 2016 | breast cancer | Agendia | Completed | No outcome recorded |
| Phase 4 | NCT01315990 Background | Jan 2011 → Mar 2015 | colorectal cancer | Dr. Carl Schimanski | Unknown | No outcome recorded |
| Phase 4 | NCT01271582 Background | Jan 2009 → Jun 2014 | colorectal cancer, gastric cancer | Asan Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00607685 Comparator | Feb 2008 → Jan 2010 | glaucoma | Singapore National Eye Centre | Completed | No outcome recorded |
| Phase 4 | NCT00531973 Comparator | Jan 2007 → Aug 2008 | female breast carcinoma | Catholic University, Italy | Unknown | No outcome recorded |
| Phase 4 | NCT01564810 Background | Sep 2006 → Jun 2012 | colorectal adenocarcinoma, metastatic malignant neoplasm | Xu jianmin | Unknown | No outcome recorded |
| Phase 4 | NCT02582970 Background | May 2005 → Oct 2007 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT01295099 Comparator | — | keloid | Queen Mary University of London | Withdrawn | No outcome recorded |
| Phase not applicable40 trials | ||||||
| — | NCT07325214 Background | Sep 2026 → Jan 2030 expected | malignant pancreatic neoplasm, pancreatic exocrine neoplasm | IMGT Co., Ltd. | Not yet recruiting | No outcome recorded |
| — | NCT07041749 Comparator | Jun 2026 → Jun 2027 expected | plantar wart | Assiut University | Not yet recruiting | No outcome recorded |
| — | NCT07543510 Background | May 2026 → Aug 2028 expected | hepatocellular carcinoma | Third Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| — | NCT07334587 Comparator | Sep 2025 → Feb 2026 overdue | colorectal carcinoma | Allama Iqbal Medical College | Enrolling by invitation | No outcome recorded |
| — | NCT07114666 Background | Aug 2025 → Aug 2029 expected | malignant pancreatic neoplasm | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07044362 Background | Jun 2025 → Oct 2026 expected | liver cancer, metastasis from malignant tumor of colon | Case Comprehensive Cancer Center | Recruiting | No outcome recorded |
| — | NCT06685588 Comparator | Jan 2025 → Jan 2026 overdue | actinic keratosis | St Vincent's University Hospital, Ireland | Not yet recruiting | No outcome recorded |
| — | NCT06867146 Comparator | Oct 2024 → Dec 2026 expected | malignant pancreatic neoplasm | Peking Union Medical College Hospital | Active not recruiting | No outcome recorded |
| — | NCT06335147 Background | Apr 2024 → Jan 2026 | metastasis from malignant tumor of colon | Henan Cancer Hospital | Unknown | No outcome recorded |
| — | NCT06055179 Background | Mar 2024 → Jun 2026 overdue | irinotecan toxicity | Guangzhou University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT07391163 Background | Jan 2024 → Jan 2026 | colorectal cancer | Tanta University | Completed | No outcome recorded |
| — | NCT05838391 Background | May 2023 → Dec 2026 expected | anal squamous cell carcinoma | Columbia University | Recruiting | No outcome recorded |
| — | NCT05599971 Comparator | Feb → Nov 2023 | plantar wart | Zagazig University | Unknown | No outcome recorded |
| — | NCT05601323 Background | Jan 2023 → May 2027 expected | pancreas disorder | SONIRE Therapeutics Inc. | Active not recruiting | No outcome recorded |
| — | NCT05520658 Comparator | Jul → Sep 2022 | plantar wart | Sohag University | Unknown | No outcome recorded |
| — | NCT05057663 Comparator | Nov 2021 → Mar 2022 | plantar wart | Sohag University | Unknown | No outcome recorded |
| — | NCT04131803 Background | Oct 2021 → Nov 2022 | colorectal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05262452 Background | Aug 2021 → Mar 2023 | chemotherapy-induced toxicity, malignant pancreatic neoplasm | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT04926545 Background | Jul 2021 → Jul 2024 | cancer, diarrheal disease | Guangzhou University of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT04710719 Comparator | Feb 2021 → Jul 2022 | keloid | Our Lady of the Lake Hospital | Completed | No outcome recorded |
| — | NCT04595929 Background | Feb 2020 → Oct 2021 overdue | gastric cancer, peritoneal carcinomatosis | St. Petersburg State Pavlov Medical University | Recruiting | No outcome recorded |
| — | NCT03591705 Background | Jul 2018 → Dec 2023 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT03838406 Background | Aug 2017 → Dec 2019 | — | Chung-Ang University | Completed | No outcome recorded |
| — | NCT05397262 Background | Mar 2017 → Dec 2098 expected | urinary bladder cancer | University of Erlangen-Nürnberg Medical School | Recruiting | No outcome recorded |
| — | NCT03045770 Background | Feb 2017 → Dec 2019 | gastroesophageal junction adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| — | NCT03213444 Comparator | Jul 2015 → Jul 2017 | colon carcinoma | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| — | NCT03690323 Background | Apr 2015 → Nov 2019 | pancreatic exocrine neoplasm | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| — | NCT03121807 Background | Sep 2014 → Apr 2019 | gastric cancer | Kaohsiung Medical University Chung-Ho Memorial Hospital | Completed | No outcome recorded |
| — | NCT02256800 Background | Aug 2014 → Nov 2017 | colorectal cancer | Jaw-Yuan Wang, MD, PhD | Completed | No outcome recorded |
| — | NCT01941173 Background | Jan → Jul 2014 | rectal cancer | City of Hope Medical Center | Withdrawn | No outcome recorded |
| — | NCT01834014 Background | May 2013 → Mar 2017 | metastasis from malignant tumor of colon | EPS Corporation | Completed | No outcome recorded |
| — | NCT01845779 Background | Sep 2012 → Jul 2019 | anal canal cancer, human papilloma virus infection | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| — | NCT01646853 Background | Aug 2012 → Dec 2013 | esophageal cancer | Simcere Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| — | NCT01125020 Comparator | Dec 2008 → May 2010 | hepatocellular carcinoma | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT00817895 Comparator | Dec 2008 → Dec 2009 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Completed | No outcome recorded |
| — | NCT00825669 Comparator | Dec 2008 → Dec 2009 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Completed | No outcome recorded |
| — | NCT00724503 Comparator | Aug 2006 → May 2015 | colorectal carcinoma, metastasis from malignant tumor of colon | Sirtex Medical | Completed | No outcome recorded |
| — | NCT00629863 Background | Sep 2004 → Sep 2009 | esophageal cancer, gastric cancer | North Wales Organisation for Randomised Trials in Health | Completed | No outcome recorded |
| — | NCT00309920 Background | Jan 2004 → ? | female breast carcinoma | Heinrich-Heine University, Duesseldorf | Unknown | No outcome recorded |
| — | NCT00004891 Background | Sep 1999 → Mar 2007 | colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04446793 Background | — | colorectal cancer | Cardiff Oncology | No longer available | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-10-18 | Takeda | Shire Granted EU Marketing Authorization of ONIVYDE®, In Combination With 5-Fluorouracil (5-FU) And Leucovorin (LV), For The Treatment of Metastatic Adenocarcinoma Of The Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy takeda.com ↗ |
| 2015-04-06 | Amgen | European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer amgen.com ↗ |
| 2015-02-27 | Amgen | Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer amgen.com ↗ |
Evidence & citations 46 cited values
Every value below carries the sentence it was read from. 2,893 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fluorouracil | “Patients will be administered with appropriate adjuvant chemotherapy regimens including but are not limited to: GEM monotherapy/adjustable GEM monotherapy, S-1...” NCT06966440 ↗1134“Patients were randomly assigned (1:1; block size of three), without stratification, to receive FOLFIRI (irinotecan 180 mg/m2, calcium folinate 400 mg/m2 or levofolinate 200...” PMID 36739879 ↗ Feb 2023 “Fluorouracil, 1000 mg/m2 per day, intravenously for days 1 to 4; cisplatin, 70 mg/m2 (or carboplatin, area under the curve, 5) intravenously on day 1; and pembrolizumab, 200...” PMID 40965911 ↗ Nov 2025 “modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a...” PMID 30575490 ↗ Dec 2018 “Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2...” NCT02527772 ↗ “Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour...” NCT06846346 ↗ “Randomization to receive 400 mg sorafenib twice daily (sorafenib group) or 400 mg sorafenib twice daily plus HAIC (SoraHAIC group) (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2,...” PMID 31070690 ↗ Jul 2019 “oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion...” NCT06346197 ↗ “This phase II trial included patients with clinical T1-T3abN0 low- or mid-rectal adenocarcinoma eligible for endoscopic resection who were treated with 3 months of chemotherapy...” PMID 35981270 ↗ Aug 2022 “The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil,...” PMID 32930387 ↗ Oct 2020 “The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil ,...” NCT05007587 ↗ “NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous...” NCT06429904 ↗ “Nanoliposomal irinotecan plus fluorouracil/leucovorin chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nab...” NCT04037241 ↗ “This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil...” NCT05575635 ↗ “This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil...” NCT00779311 ↗ “FOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 and fluorouracil 400 mg/m\^2 given as a bolus followed by 2400 mg/m\^2 given as a 46-hour...” NCT06278454 ↗ “The study focuses on advanced metastatic pancreatic cancer, testing a combination of low-dose anti-cancer drugs (G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and...” NCT06233877 ↗ “The objective of this study was to evaluate safety and anti-tumour activity of fluorouracil, leucovorin, irinotecan plus oxaliplatin (FOLFIRINOX) as salvage treatment in...” PMID 31919404 ↗ Jan 2020 “Participants will then receive an intraperitoneal fluorouracil bolus of 400 mg/m2 administered over 1 to 2 minutes followed by a continuous intraperitoneal fluorouracil...” NCT05913674 ↗ “Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days;...” NCT03975049 ↗ “mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/...” NCT02960061 ↗ “G-FLIP regimen is a combination of low doses (doses lower than those approved by the FDA and used in the clinic) of several anti-cancer drugs, Gemcitabine, Fluorouracil,...” NCT01905150 ↗ “combined with fluorouracil plus leucovorin, oxaliplatin, and albumin bound paclitaxel (Nab-POF) regimen in the treatment of patients with unresectable locally advanced or...” NCT04510064 ↗ “Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer:...” PMID 38181312 ↗ Jan 2024 “TPF (Paclitaxel micelles or albumin-bound paclitaxel 100 mg/m2, cisplatin 30 mg/m2, fluorouracil 200 mg/m2 IV drip + 1000 mg/m2 pump for 44 hours, leucovorin/calcium 200 mg) +...” NCT07469241 ↗ “PURPOSE: To assess the effects of bevacizumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) as first-line treatment of RAS mutant unresectable colorectal...” PMID 32749938 ↗ Aug 2020 “Drug used in chemotherapy such as oxaliplatin leucovorin and Fluorouracil work in different way to stop the growth of tumor cells either by killing the cells or by stopping...” NCT00578201 ↗ “Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three...” NCT02586025 ↗ “FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV...” NCT01836432 ↗ “NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous...” PMID 37708904 ↗ Sep 2023 “Neoadjuvant chemotherapy regimen will consist of six cycles of fluorouracil 500mg/m2 , epirubicin 75mg/m2 and cyclophosphamide 500mg/m2 administered intravenously at three week...” NCT03696004 ↗ “Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or...” NCT03398291 ↗ “The purpose of this study is to test the safety, activity and best doses of FOLFOX-A which consists of the standard chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and...” NCT01744353 ↗ “folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle)” NCT04587128 ↗ “Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.” NCT00258323 ↗ “Hepatic arterial infusion chemotherapy with FOLFOX regimen (oxaliplatin 85 mg/m², leucovorin 400 mg/m², fluorouracil 400 mg/m² bolus then 2400 mg/m² continuous infusion over 24 hours).” NCT07543783 ↗ “oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and fluorouracil 400 mg/m2 IV, fluorouracil 2400 mg/m2 IV (a 46 hrs CI), day 1 of each treatment cycle, every 2 weeks, given with nivolumab” NCT03921684 ↗ “AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery” NCT02620280 ↗ “Intraperitoneal chemotherapy (fluorouracil + nab-paclitaxel + cisplatin + interleukin-2) PLUS systemic chemotherapy (SOX regimen: oxaliplatin + tegafur-gimeracil-oteracil potassium)” NCT07034742 ↗ “OBJECTIVES: * Compare, by intention to treat analysis, feasibility and efficacy of 4 courses of docetaxel, cisplatin, and fluorouracil as preoperative or postoperative chemotherapy” NCT00005060 ↗ “mFOLFOX6 (oxaliplatin 85 mg/m2 on day 1 followed by lederfolin 200 mg m2 on day 1, fluorouracil 400 mg m2 on day 1 and 2,400 mg m2 continuous infusion over 46 hours every 2 weeks)” NCT07213557 ↗ “Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.” PMID 24982456 ↗ Jun 2014 “mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks.” NCT06607107 ↗ “In 2011, the PRODIGE trial has shown that oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was associated with a survival advantage but had increased toxicity.” NCT06249321 ↗ “oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w” NCT05022030 ↗ “Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;” NCT06231680 ↗ “Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.” PMID 34648352 ↗ Oct 2021 “Chemotherapy regimens based on fluorouracil (5-FU), such as CAPOX with a 3-week cycle or mFOLFOX6/FOLFIRI/FOLFOXIRI with a 2-week cycle, may be combined with targeted therapy.” NCT06794086 ↗ “Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.” NCT02004262 ↗ “intravenous liposomal irinotecan (70 mg/m2 for 90 min) plus intravenous leucovorin (400 mg/m2 for 30 min) and intravenous fluorouracil (2400 mg/m2 for 46 h) every 2 weeks” PMID 34656226 ↗ Oct 2021 “The CONKO-003 phase III study reported a survival benefit with second-line fluorouracil (FU) and oxaliplatin using the oxaliplatin, folinic acid, and FU (OFF) regimen.” PMID 27621395 ↗ Sep 2016 “fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours” NCT01478594 ↗ “Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas” PMID 40454643 ↗ Jun 2025 “fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.” NCT00321828 ↗ “Modified oxaliplatin, leucovorin, irinotecan and fluorouracil (mFOLFIRINOX) will be administered intravenously within 2 days after administration of zolbetuximab.” NCT06396091 ↗ “mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2 d1+5-FU 400mg/m2d1 /2400mg/m2 continuous intravenous injection (civ) for 46h” NCT06329947 ↗ “Patients with a poor response to docetaxal/herceptin will receive Fluorouracil, Epirubicin Hydrochloride, Cyclophonsphamide (FEC) injection by drip every 3 weeks.” NCT03879577 ↗ “continuous intravenous infusion of fluorouracil 2400mg / m², for 46 hours, leucovorin 400mg / m², irinotecan 135mg / m², and oxaliplatin 68mg / m², every 2 weeks” NCT06888648 ↗ “Includes Hepatic Arterial Infusion Chemotherapy (HAIC) with mFOLFOX6 (Oxaliplatin, Leucovorin, Fluorouracil), oral Lenvatinib, and an intravenous PD-1 inhibitor.” NCT07282184 ↗ “mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.” NCT04288999 ↗ “Sorafenib is used in combination with irinotecan, leucovorin and fluorouracil in patients with advanced colorectal cancer after failure of oxaliplatin treatment” NCT00839111 ↗ “The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.” NCT02826837 ↗ “FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles” NCT06893887 ↗ “Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.” NCT02125136 ↗ “Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 22 hours on days 1 and 2.” NCT00265811 ↗ “mFOLFOX6 (day 1, oxaliplatin 85 mg/m², folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then 2400 mg/m² over 46 h continuous infusion)” NCT01564810 ↗ “Fluorouracil and platinum were used as the basic chemotherapy regimens, with or without targeted therapy, and no additional injection of PCSK9 inhibitors” NCT06391905 ↗ “Fluorouracil 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) and 1,200 mg/m2 administered intravenously (Days 1 to 2 of FOLFOX therapy)” NCT05394740 ↗ “FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.” NCT00959647 ↗ “using a second-line regimen primarily based on fluorouracil, such as a tri-weekly CAPOX or a bi-weekly mFOLFOX6/FOLFIRI/FOLFOXIRI + targeted therapy” NCT06767007 ↗ “chemotherapy drugs (oxaliplatin, fluorouracil and leucovorin; FOLFOX-based regimen) will be intra-arterially administered though the microcatheter.” NCT06904183 ↗ “chemotherapy drugs (oxaliplatin, fluorouracil and leucovorin; FOLFOX-based regimen) will be intra-arterially administered though the microcatheter.” NCT06492395 ↗ “Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles” NCT00705627 ↗ “Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.” NCT03788226 ↗ “BACKGROUND: FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens” PMID 32867715 ↗ Aug 2020 “Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)” NCT02580253 ↗ “FOLFOX: Leucovorin 400 mg/m2, day 1, fluorouracil 400 mg/m2, day 1 and 1200 mg/m2, days 1-2, and oxaliplatin 85 mg/m2, day 1, every 2 weeks.” NCT06121700 ↗ “Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.” NCT02697838 ↗ “Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.” NCT04121039 ↗ “Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.” NCT03244774 ↗ “FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv;” NCT06420908 ↗ “modified FOLFOX 6 comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.” NCT00958737 ↗ “fluorouracil 400 mg/m2 IV push on Day 1, and fluorouracil 1,200 mg/m2 IV continuous infusion on Days 1-2 every 14 days for up to 9 cycles” NCT06719362 ↗ “FOLFIRI is a combination of three drugs: (leucovorian, fluorouracil, and irinotecan) used to treat advanced metastatic colorectal cancer.” NCT06867822 ↗ “followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours” NCT02162563 ↗ “FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3)” NCT03869034 ↗ “90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks” NCT05480306 ↗ “oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2 intravenously every 14 days for 6 cycles” PMID 33862000 ↗ Apr 2021 “Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.” NCT04595266 ↗ “FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.” NCT06225843 ↗ “mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.” NCT04396821 ↗ “then fluorouracil 400 mg/m\^2 administered as an IV bolus, then 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours” NCT00636610 ↗ “It consists of irinotecan, leucovorin, and fluorouracil (5-FU) administered sequentially over a 46-hour infusion period per cycle.” NCT07381309 ↗ “This treatment will be followed by fluorouracil (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2” NCT02311439 ↗ “Fluorouracil was injected intravenously at 400mg/m2 on day 1, followed by 1200mg/ (m2·d) × 2d with continuous intravenous infusion” NCT06239870 ↗ “400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.” NCT01862003 ↗ “mFOLFOX6（Oxaliplatin: 85 mg/m2，LV ：400mg/m2，Fluorouracil： 400mg/m2 d1，2400 mg/m2 continuous intravenous drip for 46-48 hours；q2w）” NCT06335147 ↗ “This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus” NCT02440958 ↗ “Docetaxel plus trastuzumab for 9 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide in both groups.” PMID 29852043 ↗ Sep 2018 “FOLFIRINOX (14-day cycle) included oxaliplatin (standard dose), folinic acid, fluorouracil and irinotecan (150 or 180mg/m²).” PMID 38987363 ↗ Jul 2024 “F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis” NCT06047379 ↗ “Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets” NCT05313282 ↗ “followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.” NCT05312398 ↗ “Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets” NCT04191889 ↗ “fluorouracil 400 mg/m2 IV bolus on Day 1, fluorouracil 2400 mg/m2 IV continuous infusion over 46-48 hours starting on Day 1” NCT06790706 ↗ “50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles” NCT05713838 ↗ “All patients received 4 treatments of modified FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) before SBRT.” PMID 27475674 ↗ May 2016 “combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab” NCT03567629 ↗ “Folfirinox comprises the following: Fluorouracil 2,400 mg/m2 intravenously over 48 hours Days 1-3 and 15-17 every 4 weeks” NCT03600623 ↗ “Fluorouracil 400 mg/m², IV bolus dose on day 1, followed by continuous IV infusion of fluorouracil 1600 mg/m² over 2 days” NCT02359968 ↗ “Fluorouracil 400 mg/m², intravenous bolus, Day 1, followed by 1200 mg/(m²·d) continuous intravenous infusion for 2 days” NCT07229846 ↗ “Fluorouracil: 400 mg/m² IV bolus at Hour 3 on Day 1, followed by 2400 mg/m² as a continuous IV infusion over 24 hours.” NCT07328009 ↗ “Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)” NCT00915850 ↗ “neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab” NCT01340430 ↗ “fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m² as a 46 hour continuous IV infusion, every 2 weeks” NCT06529718 ↗ “All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2” NCT01829178 ↗ “It is a combination of leucovorin calcium (folinic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin” NCT06483555 ↗ “modified folinic acid (leucovorin), fluorouracil, and oxaliplatin will be administered at a protocol-defined dose” NCT06835569 ↗ “and fluorouracil at a dose of 750 mg per square meter per day, administered by continuous infusion on days 1 to 5” NCT01525927 ↗ “fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles” NCT01703390 ↗ “neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery.” NCT03979131 ↗ “the control group (n=28) which received 6 cycles of folinic acid, fluorouracil and irinotecan (FOLFIRI) regimen” PMID 35022282 ↗ Jan 2022 “Fluorouracil: 400 mg/m2 as a bolus injection given after a two-hour leucovorin infusion at a dose of 400 mg/m2.” NCT04625803 ↗ “HAIC: oxaliplatin 100 mg/m2, leucovorin calcium 200 mg/m2, fluorouracil 2000 mg/m2 24-hour drip, q4w, 2 cycles;” NCT05511051 ↗ “Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home.” NCT05121038 ↗ “fluorouracil 400 mg/m2 intravenous bolus followed by fluorouracil 2400 mg/m2 continuous infusion over 23 hours” NCT06143579 ↗ “Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy.” NCT06005324 ↗ “HAIC：administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks” NCT06867432 ↗ “a 400 mg/m² intravenous bolus of fluorouracil, and a 600 mg/m² continuous infusion of fluorouracil for 22 hr” NCT05316818 ↗ “Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin” NCT02856126 ↗ “Drug: Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.” NCT05412589 ↗ “Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Bevacizumab and Sintilimab for injection.” NCT05214339 ↗ “Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin” NCT03469479 ↗ “fluorouracil (1000 mg per square meter per day) was administered as a continuous 24-hour infusion for 4 days” NCT01425736 ↗ “6 cycles of mFOLFOX6 (oxaliplatin, leucovorin and fluorouracil) followed by long course chemoradiotherapy” NCT04293419 ↗ “perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) plus surgery” PMID 39842010 ↗ Jan 2025 “Folfox chemotherapy (folinic acid, fluorouracil and oxaliplatin) for 6 weeks (3 courses) before surgery.” NCT06293625 ↗ “fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour continuous IV infusion” NCT07359456 ↗ “Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump” NCT03788174 ↗ “either cetuximab and irinotecan or cetuximab and FOLFIRI (folinic acid, fluorouracil, and irinotecan)” PMID 31566309 ↗ Sep 2019 “5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.” NCT01992705 ↗ “Combination of fluorouracil (FU), oxaliplatin, and irinotecan (FOLFIRINOX) is superior to gemcitabine” PMID 40378359 ↗ May 2025 “Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle” NCT06172205 ↗ “Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.” NCT06736717 ↗ “and fluorouracil [400 mg/m2 bolus] all on day 1, and fluorouracil [2400 mg/m2 infusion] on days 1-2.” PMID 36328033 ↗ Oct 2022 “Fluorouracil 5-FU continuous infusion: 400mg/m2 on Dand then 2400mg/m2 for 46h of each 21 day cycle” NCT07267806 ↗ “FOLFIRI (leucovorin [folinic acid], fluorouracil, and irinotecan) plus cetuximab induction therapy” PMID 37721754 ↗ Sep 2023 “plus fluorouracil 700-850 mg/m² daily by continuous intravenous infusion over 24 hours on Days 1-5” NCT07446335 ↗ “Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2” NCT01642771 ↗ “Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours” NCT05476432 ↗ “Fluorouracil: 400 mg/m2 push infusion and given 600mg/m2 intravenously 22 hours later， D1、D2, Q2W” NCT05355155 ↗ “Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion” NCT04145193 ↗ “Patients receive fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1.” NCT00433589 ↗ “bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion” NCT05399394 ↗ “* Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2” NCT04176952 ↗ “standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2)” NCT01537536 ↗ “Fluorouracil (400 mg/m\^2 bolus followed by 2,400 mg/m\^2 continuous infusion over 46-48 hours)” NCT01595321 ↗ “Arm B will receive leucovorin, fluorouracil, and irinotecan every two weeks through an infusion” NCT05419479 ↗ “fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour” NCT03690323 ↗ “NALIRIFOX (liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin)” NCT06816914 ↗ “IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.” NCT02826486 ↗ “post-surgery combination chemotherapy in the abdomen with fluorouracil (5-FU) and paclitaxel.” NCT00004547 ↗ “FOLFIRINOX is comprised of four drugs: Oxaliplatin, irinotecan, fluorouracil and leucovorin.” NCT01821729 ↗ “administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries” NCT03812770 ↗ “administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries” NCT03722498 ↗ “then fluorouracil 400 mg/m² bolus infusion and 2400 mg/m² continuous infusion over 24 hours” NCT07543510 ↗ “administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries” NCT03468231 ↗ “hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment” NCT06134193 ↗ “Fluorouracil iv bolus 400mg/m2, D1 + Fluorouracil 2400mg/m2 continuous infusion for 46-48h” NCT06616259 ↗ “hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment” NCT05524155 ↗ “hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment” NCT05029973 ↗ “Fluorouracil (5-FU), leucovorin and oxaliplatin are considered traditional chemotherapies” NCT00116506 ↗ “Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2” NCT04986930 ↗ “fluorouracil 400 mg/m2 bolus at hour 5, and then fluorouracil 2,400 mg/m2 over 46 hours” NCT03164382 ↗ “Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2.” NCT02534337 ↗ “PF : fluorouracil 750-1000mg/m2, CIV 96 hours，cisplatin 75mg/m2, d1, iv, q4w，2 cycles.” NCT07112833 ↗ “FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion” NCT05593328 ↗ “FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion” NCT06106308 ↗ “leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\]” NCT06149689 ↗ “Fluorouracil + leucovorin (calcium folinate) + irinotecan via intravenous infusion.” NCT07702032 ↗ “either Fluorouracil (5-FU) or Capecitabine or other Standard of Care Chemotherapy” NCT05315830 ↗ “Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.” NCT05617430 ↗ “Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.” NCT06244225 ↗ “modified regimen of oxaliplatin, leucovorin, irinotecan, and fluorouracil (5-FU)” NCT04089150 ↗ “The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil.” NCT03941093 ↗ “NALIRIFOX (liposomal irinotecan hydrochloride with fluorouracil and oxaliplatin)” NCT07077551 ↗ “infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump” NCT03707639 ↗ “Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.” NCT02724202 ↗ “standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy” PMID 26903575 ↗ Feb 2016 “1200 mg per m2 per day of fluorouracil for 2 days, every 2 weeks intravenously” PMID 38547895 ↗ Apr 2024 “BOLD-100 +/- Folinic acid (leucovorin), Fluorouracil (5-FU), and Oxaliplatin.” NCT04421820 ↗ “Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin” NCT03899636 ↗ “Fluoropyrimidine (fluorouracil or capecitabine) with carboplatin or cisplatin” NCT06084897 ↗ “fluorouracil [5-FU], leucovorin [LV], and irinotecan/nanoliposomal irinotecan” PMID 41187298 ↗ Nov 2025 “Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles” NCT01326559 ↗ “modified leucovorin, fluorouracil, irinotecan, and oxaliplatin [mFOLFIRINOX]” PMID 40184561 ↗ Apr 2025 “receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses” NCT00003953 ↗ “folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin (mFOLFOX6)” NCT02102022 ↗ “5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion” NCT05004350 ↗ “fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes” NCT05712356 ↗ “adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion” NCT01771146 ↗ “Fluorouracil 2600 mg/m2 continuous infusion over 24 hours daily on Day 1” NCT05733689 ↗ “Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium” NCT06572813 ↗ “docetaxel, oxaliplatin, fluorouracil, and leucovorin (the FLOT regimen)” NCT06411171 ↗ “continuous infusion of fluorouracil (800 mg/m(2) per day, on days 1-5)” PMID 19818685 ↗ Oct 2009 “fluorouracil: 400 mg/m2 bolus or 2400 mg/m2 46 hrs continuous infusion” NCT05087992 ↗ “Chemotherapy is the oxaliplatin combination with fluorouracil regimen.” NCT02860429 ↗ “Drug: Fluorouracil Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV bolus” NCT03488667 ↗ “Carac cream (fluorouracil) 0.5% applied daily on the face for one week” NCT03037541 ↗ “fluorouracil 500mg/m2, 20min, day 1 + fluorouracil 1500mg/m2, 20h, q3w” NCT07012798 ↗ “combined with either continuous infusion fluorouracil or capecitabine” NCT06052332 ↗ “Hepatic Arterial Infusion of Oxaliplatin Plus Fluorouracil/Leucovorin” NCT05821361 ↗ “Fluorouracil 400 mg/m2 Day 1 Fluorouracil 2400 mg/m2 48 hrs infusion” NCT03528876 ↗ “Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks” NCT02486601 ↗ “folinic acid [FA] + fluorouracil [5-FU] + oxaliplatin [mFOLFOX-6]” NCT01111604 ↗ “leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin” NCT04418895 ↗ “F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite” NCT01523457 ↗ “Fluorouracil "bolus" 400mg/m², Fluorouracil: 2400mg/m² over 46h” NCT07118800 ↗ “FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) therapy” PMID 29800971 ↗ Jul 2018 “fluorouracil 2400 mg/m², d1-2, continuous pumping for 46 hours” NCT04908566 ↗ “fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2” NCT01035385 ↗ “* mFFX: Oxaliplatin, Folinic acid, Fluorouracil and Irinotecan” NCT06518538 ↗ “Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)” NCT03058939 ↗ “fluorouracil 2400 mg/m2, administered as 46-hour iv infusion” NCT04431258 ↗ “fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus” NCT03874026 ↗ “FOLFOX (fluorouracil, leucovorin, oxaliplatin) chemotherapy” NCT03781323 ↗ “Fluorouracil for solution for infusion (IV administration)” NCT06967987 ↗ “mFOLFIRINOX:Fluorouracil+leucovorin+Irinotecan+Oxaliplatin” NCT06913218 ↗ “Topical 5-FU (fluorouracil) pretreatment prior to dovonex” NCT06685588 ↗ “Fluorouracil 400 mg/m² as a fast infusion over 15 minutes” NCT02128100 ↗ “Fluorouracil 2400 mg/m\^2 continuous intravenous drip 46h” NCT03633734 ↗ “fluorouracil IV over 46 hours beginning on days 1 and 15” NCT01417494 ↗ “infusion of fluorouracil (2400 mg/m2) was administered” NCT04174339 ↗ “combination of Fluorouracil, leucovorin and irinotecan” NCT02033551 ↗ “Fluorouracil 400 mg/m², intravenous infusion on Day 1” NCT07381400 ↗ “oxaliplatin + calcium folinate + fluorouracil regimen” NCT04198051 ↗ “Fluorouracil at a dose of 400 mg/m² iv bolus (day 1)” NCT03647969 ↗ “Nanoliposomal irinotecan, Fluorouracil, Levofolinate” NCT05601323 ↗ “methotrexate IV and fluorouracil IV on days 1 and 8” NCT00024102 ↗ “Folinic acid, Irinotecan, fluorouracil, oxaliplatin” NCT03822936 ↗ “mFOLFIRINOX (Oxaliplatin, Irinotecan, Fluorouracil)” NCT03891472 ↗ “Fluorouracil/Leucovorin, Oxaliplatin (5-FU/LV, OX)” NCT07074353 ↗ “FOLFOX4 (leucovorin + fluorouracil + oxaliplatin)” NCT02069041 ↗ “Fluorouracil 500 mg/m² by i.v. bolus or infusion” NCT00256360 ↗ “Fluorouracil#2600mg/m2,intravenous drip for 24h#” NCT04341857 ↗ “FOLFOX (folinic acid, fluorouracil, oxaliplatin)” NCT00994864 ↗ “Fluorouracil 500mg/m2 by i.v. bolus or infusion.” NCT00286819 ↗ “Leucovorin + Fluorouracil (5-FU) + Oxaliplatin” NCT00599924 ↗ “HAIC: Oxaliplatin plus Fluorouracil/Leucovorin” NCT05864755 ↗ “Oxaliplatin, Fluorouracil, calcium leucovorin” NCT05590117 ↗ “4. Fluorouracil (FU)-400 mg/m2 IV bolus Day 1” NCT03291899 ↗ “fluorouracil, 425 mg/m2/day on day1\~5, i.v.” NCT01197118 ↗ “Fluoro-uracil \[800 mg/m2, day 1 to day 5\]” NCT01248299 ↗ “* Fluorouracil * Oxaliplatin * Folinic acid” NCT04793958 ↗ “Fluorouracil (5FU) bolus 400 mg/m2 iv day 1” NCT05527782 ↗ “Oxaliplatin , fluorouracil, and leucovorin” NCT03812783 ↗ “Oxaliplatin , fluorouracil, and leucovorin” NCT03803254 ↗ “Oxaliplatin , fluorouracil, and leucovorin” NCT04962958 ↗ “Oxaliplatin , fluorouracil, and leucovorin” NCT02981498 ↗ “Fluorouracil 2400mg/m2，iv，D1, 14days/cycle” NCT04324307 ↗ “Fluorouracil 2400 mg per square meter IV” NCT06048484 ↗ “Fluorouracil 2.4 g/m\^2 IV over 46 hours” NCT02405585 ↗ “Fluorouracil 2600mg/m2 over 24 hours iv” NCT03399071 ↗ “Fluorouracil 2400 mg/m² during 46 hours” NCT06813976 ↗ “Oxaliplatin + leucovorin + fluorouracil” NCT03662659 ↗ “Oxaliplatin + leucovorin + fluorouracil” NCT06123455 ↗ “- Epirubicin + Cisplatin + Fluorouracil” NCT00718354 ↗ “fluorouracil (5-FU) 400 mg/m² IV bolus” NCT07437287 ↗ “fluorouracil, leucovorin, oxaliplatin” NCT06385925 ↗ “Fluorouracil 500 mg/m2, every 3 weeks” NCT02001506 ↗ “Fludarabine, Fluorouracil, Gefitinib” NCT02788201 ↗ “folinic acid+fluorouracil+irinotecan” NCT01183494 ↗ “Fluorouracil will be administered at” NCT05585320 ↗ “fluorouracil 2400 mg/m\^2 for 24-48h” NCT06363825 ↗ “5-fluorouracil 500 mg/㎡ iv days 1,8” NCT01917578 ↗ “infusional fluorouracil, 2400 mg/m2” PMID 35834226 ↗ Sep 2022 “Fluorouracil, Adriamycin, Cytoxan” NCT02995772 ↗ “5% 5-fluorouracil (5-FU) powder” NCT07401277 ↗ “Fluorouracil 400 mg/m² IV bolus” NCT03377842 ↗ “Fluorouracil bolus 400 mg/m2 IV” NCT05721872 ↗ “Fluorouracil (5-FU) 400mg/m2 IV” NCT03838406 ↗ “fluorouracil or capecitabine” NCT03023436 ↗ “5- fluorouracil 2400mg/m\^2” NCT03977272 ↗ “Drug: fluorouracil Given IV” NCT03641976 ↗ “fluorouracil 1200mg/m²/day” NCT04423965 ↗ “5-fluorouracil (500mg/m2)” NCT00798070 ↗ “Fluorouracil (5-FU): Q2W;” NCT07047560 ↗ “Fluorouracil 500 mg/m2 iv” NCT01433562 ↗ “Fluorouracil 2400 mg/m²” NCT03982121 ↗ “cisplatin, Fluorouracil” NCT00992199 ↗ “Fluorouracil Injection” NCT07262567 ↗ “fluorouracil 400 mg/m²” NCT06919848 ↗ “Adrucil, fluorouracil” NCT02046538 ↗ “Fluorouracil 600mg/m2” NCT00309478 ↗ “5-FU \[fluorouracil)” NCT04009876 ↗ “Fluorouracil or 5-FU” NCT04553692 ↗ “5-FU (fluorouracil)” NCT00291785 ↗ “5FU (fluorouracil)” NCT02648711 ↗ “5-FU; Fluorouracil” NCT03563170 ↗ “Fluorouracil” NCT00591123 ↗ “Fluorouracil” NCT00798070 ↗ “Fluorouracil” NCT05704985 ↗ “Fluorouracil” NCT01703910 ↗ “fluorouracil” NCT02241551 ↗ “Fluorouracil” NCT05346484 ↗ “fluorouracil” NCT03303495 ↗ “fluorouracil” NCT02887313 ↗ |
| Known as | 5 FLUOROURACYL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02842580 ↗ |
| Known as | 5 fluouracil | “5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)” NCT03069950 ↗1“continuous 5 fluouracil infusion plus long-acting octreotide” NCT00953394 ↗ |
| Known as | 5 FU (Adrucil) | “5 FU (Adrucil)” NCT02178709 ↗ |
| Known as | 5- fluorine pyrimidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03982680 ↗ |
| Known as | 5-flourouracil | “the control group (n=28) which received 6 cycles of folinic acid, fluorouracil and irinotecan (FOLFIRI) regimen (5-flourouracil, leucovorin, irinotecan)” PMID 35022282 ↗ Jan 2022 |
| Known as | 5-fluorouracil | “Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the...” NCT01542931 ↗1065“Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2...” NCT00778830 ↗ “Patients presented with non-keratinizing NPC and stage AnyTN2-3M0 and plasma EBV DNA≥1500copies/ml are randomly assigned to receive TPF(paclitaxel...” NCT03306121 ↗ “Definitive chemoradiation involved induction chemotherapy with 5-fluorouracil (5-FU) (650 mg/mg(2)/day), cisplatin (15 mg/mg(2)/day), and paclitaxel (200 mg/mg(2)/day) for two...” PMID 21507583 ↗ Apr 2011 “After achieving objective tumor response or stable disease after 3 cycles of capecitabine and oxaliplatin or 4 cycles of 5-fluorouracil and oxaliplatin with or without...” PMID 41837962 ↗ Apr 2026 “Treatment in this multicentric neoadjuvant pilot study consisted of panitumumab (9 mg/kg) for eight cycles q.3 weeks combined with four cycles of 5-fluorouracil, epidoxorubicin...” PMID 24827135 ↗ May 2014 “Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for...” NCT05290116 ↗ “mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes,...” NCT03099265 ↗ “The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5...” NCT04083235 ↗ “The FOLFOXIRI chemotherapy regimen (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) will be administered according to the study protocol as part of total neoadjuvant...” NCT07277842 ↗ “FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin): 4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin...” NCT02452853 ↗ “Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil +...” NCT05978349 ↗ “Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous...” NCT01446458 ↗ “Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV...” NCT04084496 ↗ “This study aimed to determine the optimal second-line treatment strategy in patients with metastatic pancreatic cancer, hypothesizing that liposomal irinotecan (nal-IRI)...” PMID 41921365 ↗ Mar 2026 “This study will define the maximum tolerated dose of paclitaxel and 5-fluorouracil (5-FU) given as an early post-operative intraperitoneal (IP) dwell therapy after...” NCT00001569 ↗ “FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil \[5-FU\], and 2400 mg/m\^2 continuous intravenous infusion 5-FU over 46 hours) will be...” NCT04446793 ↗ “Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant cisplatin (80mg/m2 on day 1)...” NCT03321539 ↗ “Participants enrolled will receive QL1706 (5 mg/kg, Q3W, d1) + docetaxel (50 mg/m², Q3W, d1) + oxaliplatin (100 mg/m², Q3W, d1) + leucovorin (LV) (400 mg/m², Q3W, d1) +...” NCT07400315 ↗ “We evaluated the efficacy and the toxicity of a novel regimen of daily low-dose nedaplatin (cis-diammine-glycolatoplatinum) and continuous infusion of 5-fluorouracil (5-FU)...” PMID 19930599 ↗ Nov 2009 “The chemotherapy regimen consisted of intraperitoneal cisplatin soon after abdominal closure, postoperative intravenous cisplatin (day 14) and 5-fluorouracil (day 14-16), and...” PMID 21336855 ↗ Feb 2011 “FOLFOX4, comprising infusional 5-fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin, with cetuximab compared with UFOX, comprising UFT, an oral prodrug of 5-FU, LV, and...” PMID 24370353 ↗ Nov 2013 “Participants received up to 12 treatments of 5-fluorouracil over 4 or more cycles administered by IV bolus 400 mg/m\^2 over 5 to 15 minutes followed by 2400mg/m\^2 over 46-48...” NCT03504397 ↗ “Each cycle of FLOT(D) consists of 5-fluorouracil 2600 mg/m2 administered over 24 hours, leucovorin 200 mg/m2 administered over 2 hours, oxaliplatin 85 mg/m2 administered over 2...” NCT07700420 ↗ “The objective of this exploratory study was to examine the association of low skeletal muscle, commonly known as sarcopenia, on the pharmacokinetics (PKs) of 5-fluorouracil...” PMID 29159476 ↗ Nov 2017 “This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2,...” NCT02468557 ↗ “This multicenter phase II non-comparative trial evaluated the addition of aflibercept to infusional 5-fluorouracil/folinic acid (LV5FU2 regimen) as first-line treatment in...” PMID 38672597 ↗ Apr 2024 “Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed...” NCT03288350 ↗ “BACKGROUND: FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with...” PMID 32921581 ↗ Jun 2020 “The regimen tested consisted of bevacizumab (5 mg/kg), folinic acid(400 mg/m²), 5-fluorouracil (2400 mg/m² for 46 h), oxaliplatin (85 mg/m²) and irinotecan (70 mg/m²...” PMID 39913183 ↗ Feb 2025 “D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400 mg / m², 5-fluorouracil 400mg / m² in bolus followed by continuous administration over...” NCT05065801 ↗ “Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose),...” NCT04185883 ↗ “HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a...” NCT04217954 ↗ “Fluropyrimidines (FPs), such as 5-Fluorouracil (5-FU) and Capecitabine, are cornerstone chemotherapy agents widely used in the treatment of various cancers, including...” NCT07158164 ↗ “Another medication, called 5-fluorouracil (5-FU), has been shown in prior studies to work well when combined with steroids, but it is usually given by injection, which can be...” NCT07660120 ↗ “Once eligibility has been confirmed and the patient has been registered to the study, the patient will begin induction modified FOLFIRINOX (Oxaliplatin, Leucovorin, Irinotecan,...” NCT05132504 ↗ “Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil,...” NCT01505530 ↗ “Patients with an unresectable metastatic colorectal carcinoma (mCRC) histologically proven will be treated with a combination of...” NCT02173990 ↗ “mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1)...” NCT05571644 ↗ “Concurrently, patients will receive docetaxel (20 mg/m2) IV weekly (Monday) and 5-fluorouracil (300 mg/m2) as a 24 hour continuous infusion for 5 of 7 days (Monday-Friday) of...” NCT00561197 ↗ “FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous...” NCT01786538 ↗ “In the University Hospital Center of Besançon, 8 patients with metastatic anal cancer were treated between 2005 and 2008 by 6 cycles of chemotherapy including taxane: DCF...” NCT01845779 ↗ “FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m²,...” NCT00508404 ↗ “this study is an investigator-initiated single-arm, phase II trial to investigate the efficacy of PIPAC combined with systemic FOLFOX (5-fluorouracil, oxaliplatin, leucovorin)...” PMID 37875869 ↗ Oct 2023 “However, a recent Phase I/II study demonstrated tolerability of the chemotherapy combination liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX) in...” NCT07076212 ↗ “PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR...” NCT00002716 ↗ “Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv)...” NCT04393298 ↗ “All patients will be planned for six two-weekly cycles of FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin and irinotecan) prior to chemoradiotherapy (25 × 2 Gy or 28 × 1.8...” PMID 36068495 ↗ Sep 2022 “The "oxaliplatin-based" group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox...” NCT03217097 ↗ “5-fluorouracil (5-FU) is an antimetabolite drug, used for several therapeutic purposes in dermatology, including premalignant and malignant lesions, keloid scars, vitiligo, and...” NCT07041749 ↗ “A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic...” NCT00056030 ↗ “A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in...” NCT00423293 ↗ “The FOLFIRINOX regimen (5-fluorouracil \[5-FU\], folinic acid, irinotecan, and oxaliplatin) and the combination of nab-paclitaxel with gemcitabine demonstrated to be more...” NCT04167007 ↗ “Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2400 mg/m2 for 48 h) every 2 weeks for total 6 cycles...” NCT05792735 ↗ “Liposomal Irinotecan (Nal-IRI) Plus 5-fluorouracil and Leucovorin (5-FU/LV) Plus Oxaliplatin (NALIRIFOX) as First-Line Chemotherapy for Patients With Advanced Small Intestine...” NCT07060014 ↗ “5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3...” NCT02896803 ↗ “Neoadjuvant treatment consisted of 2 cycles of chemotherapy with DCF (docetaxel, cisplatin, and 5-fluorouracil [5FU]) followed by preoperative CRT with oxaliplatin, continuous...” PMID 37817565 ↗ Oct 2023 “Each patient enrolled in the preoperative cohort received 5-fluorouracil (5-FU) 225 mg/m2 as a continuous infusion (IVCI) on days 1-42 through a portable infusion pump and...” NCT00308516 ↗ “Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2...” NCT02365805 ↗ “Phase II Study of Oxaliplatin in Combination With 5-fluorouracil (5-FU) and Folinic Acid (FA) in Patients Who Have Failed First-line Treatment for Locally Advanced or...” NCT00782041 ↗ “In this phase I dose-escalation trial, we assess the maximum tolerated dose (MTD) of Bermekimab in combination with Nanoliposomal Irinotecan (Nal-Iri) and...” PMID 36056179 ↗ Sep 2022 “Participants in the experimental arm will receive SCRT (25 Gy in 5 fractions, daily) followed by four cycles of FOLFOX (oxaliplatin, 5-fluorouracil, and folinic acid) as a...” PMID 37923987 ↗ Nov 2023 “5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream...” NCT04926545 ↗ “Pilot Study of Hepatic Arterial Infusion (HAI) With Oxaliplatin, Folinic Acid and 5 Fluorouracil (FOLFOX) in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From...” NCT01937507 ↗ “This is a randomized phase II multicenter controlled study of oxaliplatin, calcium folinate, and 5-fluorouracil (mFOLFOX7) as neoadjuvant chemotherapy for resectable advanced...” NCT00591045 ↗ “5-Fluorouracil (5-FU) is a chemotherapeutic agent used in the treatment of many malignant tumors and it has been approved for topical use in the treatment of several...” NCT05513924 ↗ “followed by 5 Fluorouracil (5 FU), intravenous bolus, at a dose of 400 mg/m² on D1, followed by 5 Fluorouracil (5 FU) as a 46-hour continuous infusion at a dose of 2400 mg/m²...” NCT00467142 ↗ “There will be six groups: 1) combination with paclitaxel, 2) combination with topotecan, 3) combination with doxorubicin, 4) combination with 5-fluorouracil, folinic acid, and...” NCT06840886 ↗ “One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX).” NCT04393584 ↗ “Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma.” PMID 40619376 ↗ Jul 2025 “A Phase II Study of Weekly Paclitaxel(Taxol)and 24-Hour Infusion High-Dose 5-Fluorouracil and Leucovorin(HDFL)in the Treatment Locally Advanced and Recurrent/Metastatic Gastric Cancers” NCT00154726 ↗ “mFOLFOX6 consisting of Folinic acid (Leucovorin) 400 mg/m2 (D,L racemic form) or 200 mg/m2 (L-isomer form [levo leucovorin]), 5-fluorouracil (5-FU) 2400 mg/m2 and Oxaliplatin 85 mg/m2” NCT05052099 ↗ “NALIRIFOX is a chemotherapy regimen that includes liposomal irinotecan, oxaliplatin, 5-fluorouracil (5-FU), and leucovorin, administered intravenously in 10-12 cycles every two weeks.” NCT07173387 ↗ “In Japan, oxaliplatin (OXA)/5-fluorouracil (5-FU)/leucovorin (LV)-the mFOLFOX6 regimen-is the most frequently used first-line chemotherapy backbone for metastatic colorectal cancer.” PMID 28284575 ↗ Mar 2017 “5-Fluorouracil (5FU) is proven to be the most effective therapy in field directed treatment for AK, with Jansen et al. reporting a 1-year probability of treatment success of 74.7%.” NCT06499415 ↗ “The adjuvant chemotherapy treatment based on the use of fluoropyrimidine, especially 5-fluorouracil (5-FU) is the mainstay of the pharmacological treatment of colorectal cancer.” NCT03213444 ↗ “It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.” NCT07030283 ↗ “mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles” NCT05954078 ↗ “A Phase II Study of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), and Leucovorin (CF) in Patients With Metastatic Colorectal Carcinoma Previously Treated With Irinotecan (CPT-11)” NCT00016978 ↗ “mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles” NCT04338191 ↗ “Five per cent 5-fluorouracil (5-FU) cream is a well-established treatment for actinic keratosis (AK), and ingenol mebutate gel (IMB) is a novel topical field-directed therapy.” PMID 25727104 ↗ Feb 2015 “mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)” NCT05200299 ↗ “mFOLFOX6: oxaliplatin 85 mg/m², leucovorin 400 mg/m², 5-fluorouracil 400 mg/m² IV bolus on Day 1; followed by 5-fluorouracil 2400 mg/m² continuous infusion over 46 hours, q2w” NCT07581626 ↗ “The goal of this clinical trial is to learn how well 5 fluorouracil (5FU) with micro-needling works to treat limited vitiligo as compared to strong steroid applied on skin.” NCT07398807 ↗ “Efficacy of low-dose (0.5%) 5-fluorouracil with 10% salicylic acid (5-FU/SA) has been shown in randomized comparative trials of hyperkeratotic lesions of various grades.” PMID 25257941 ↗ Sep 2014 “5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)” NCT00531973 ↗ “After induction therapy, patients will continue with maintenance therapy using bevacizumab, PD-1 inhibitor, and 5-fluorouracil (5-FU), administered every 2 weeks (Q2W).” NCT06958419 ↗ “FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours)” NCT01298570 ↗ “Patients who decide to participate in the study will receive a chemotherapy drug called 5-Fluorouracil (5FU)through an intravenous catheter continuously over 12 weeks.” NCT00188266 ↗ “The FLOT regimen consisted of four cycles of 5-Fluorouracil 2600 mg/m2, Leucovorin 200 mg/m2, Oxaliplatin 85 mg/m2, and Docetaxel 50 mg/m2, intravenous every 2 weeks.” PMID 41181842 ↗ Oct 2025 “The mFOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin) and AG regimens (gemcitabine combined with nab-paclitaxel) are commonly used regimens in clinical practice.” NCT05679050 ↗ “combination of gemcitabine, 5-fluorouracil (5-FU), and leucovorin (LV) in patients with unresectable or metastatic biliary tract or gallbladder adenocarcinoma (ACA).” PMID 15558814 ↗ Jan 2005 “Hepatic arterial infusion chemotherapy is consist of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.” NCT05171166 ↗ “The FOLFIRINOX scheme, composed of 5-fluorouracil / folinic acid, oxaliplatin and irinotecan, is recommended as neoadjuvant treatment, but the response is still low.” NCT04010552 ↗ “FOLFIRI iv every 14 days (Irinotecan 180 mg/sqm, Folinic Acid 400 mg/sqm, 5Fluorouracil 400 mg/sqm iv bolus and 2400 mg/sqm iv continuous infusion over 46-48 hours).” NCT06640166 ↗ “The regimen consists of Oxaliplatin 85 mg/m², Leucovorin 400 mg/m², and 5-Fluorouracil 2500 mg/m² given as a continuous hepatic arterial infusion over 46-48 hours.” NCT07483359 ↗ “Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma” NCT01285778 ↗ “mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1)” NCT05427669 ↗ “5-Fluorouracil plus irinotecan or oxaliplatin alone or in association with target therapy are standard first-line therapy for metastatic colorectal cancer (mCRC).” PMID 29942666 ↗ Jun 2018 “5-fluorouracil will be administered as a 400 mg/m2 intravenous bolus injection (day 1) followed by 2400 mg/m246-hours continuous infusion (day 1), every 2 weeks.” NCT04425239 ↗ “5-fluorouracil: give intravenous infusion at a dose of 400mg/m2 on the first day of chemotherapy, then give an intravenous drip at a dose of 1200mg/m2 for 2 days” NCT06269445 ↗ “The purpose of this study is to evaluate the efficacy and the toxicity of lobaplatin, 5-fluorouracil (5-FU) and leucovorin in patients with esophageal carcinoma.” NCT01034683 ↗ “5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company.” NCT02017704 ↗ “FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1)” NCT05832398 ↗ “Patients will receive ablative fractional laser (AFL)-assisted cisplatin+5-fluorouracil (5-FU) as a treatment for their cutaneous basal cell carcinoma (BCC).” NCT03541252 ↗ “irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer” NCT06172036 ↗ “HAIC- modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h)” NCT06364007 ↗ “Phase II Trial of Infusional 5 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND IRINOTECAN (FOLFIRINOX) in First Line Treatment of Advanced Biliary Tract Cancers” NCT03291899 ↗ “mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle” NCT01652976 ↗ “followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle” NCT00609622 ↗ “Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w” NCT05634590 ↗ “Patients will receive a treatment scheme of nal-IRI, oxaliplatin, Levofolinic Acid and 5-fluorouracil (5 -FU) on Day 1 and Day 15 of each 28 day cycles.” NCT03528785 ↗ “5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;” NCT01763450 ↗ “FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.” NCT03388190 ↗ “The choice of fluoropyrimidine (either 5-fluorouracil (5FU) or capecitabine) was decided by the treating physician and patient before randomisation.” PMID 19165196 ↗ Jan 2009 “5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks” NCT01494363 ↗ “consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.” NCT01611857 ↗ “5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]” NCT04952753 ↗ “HAIC was adopted of the FOFOLX 6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days.” NCT06463444 ↗ “Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.” NCT04460352 ↗ “concurrently with cisplatin (50 mg/m2, day 1) for up to 8 cycles and 5-fluorouracil (1,200 mg/m2, days 1-2) for up to 12 cycles intravenously Q2W.” PMID 39446605 ↗ Oct 2024 “Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)” NCT03176264 ↗ “5-fluorouracil (5-FU) is a standard of care in frail/elderly patients with an unresectable colorectal adenocarcinoma (CRC) in first-line setting.” NCT07124884 ↗ “Will receive a combination of BMS-986504, and the combination treatment mFOLFIRINOX (oxaliplatin, irinotecan, and 5-fluorouracil) for 4-6 months.” NCT07283705 ↗ “CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10” NCT01998906 ↗ “5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours.” NCT03343301 ↗ “Oxaliplatin and 5-fluorouracil have roles in releasing tumor antigen epitopes, activating CD8+ cells, and reshaping the immune microenvironment.” NCT06688786 ↗ “Standard chemotherapy FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) will be administered intravenously every 14 days of a 28-day cycle.” NCT06747845 ↗ “mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle.” NCT04158349 ↗ “Evaluate mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation” NCT03110926 ↗ “5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours” NCT03694522 ↗ “This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.” NCT03042780 ↗ “Efficacy of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) in high-risk pediatric retinal detachment; randomized clinical trial.” PMID 38433191 ↗ Mar 2024 “One of the most active treatment combinations is known as FOLFOX, which is a combination of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin.” NCT00478946 ↗ “Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/ m ²/day administered starting on week 1, day 1.” NCT01063075 ↗ “5-fluorouracil (5-FU)/folate, the standard of care for metastatic colorectal cancer (mCRC), have generated interest in optimizing the folate.” PMID 38059497 ↗ Jan 2024 “After progression, only 40 to 45% of patients will receive a second line chemotherapy which will include 5-fluoro-uracil (5FU) and irinotecan” NCT04325425 ↗ “FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, and 5-fluorouracil (400 mg/m2 bolus then 2400 mg/m2 over 46 h))” NCT07155629 ↗ “Standard treatment of squamous cell carcinoma of the anus (SCCA)is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT).” PMID 37315583 ↗ Jun 2023 “5-Fluorouracil (5-FU), oxaliplatin and leucovorin will be administered intravenously once every 14 days, according to the mFOLFOX-6 regimen:” NCT03000374 ↗ “Chemotherapy regimens, include gemcitabine and 5-fluorouracil (5FU) but practices are highly heterogenous due to the low level of evidence.” PMID 41622055 ↗ Jan 2026 “preoperative radiation and 5-fluorouracil-based chemotherapy (5,040 cGy to the pelvis and 2 cycles of bolus 5-fluorouracil with leucovorin)” PMID 10813118 ↗ Jan 2000 “Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,” NCT05610332 ↗ “Phase I Study Of Sunitinib In Combination With Oxaliplatin, L-Leucovorin, And 5-Fluorouracil In Patients With Metastatic Colorectal Cancer” NCT00631410 ↗ “Combination of drugs (Irinotecan, Oxaliplatin, Leucovorin, and 5-Fluorouracil (5-FU)) known as FOLFIRINOX every 2 weeks for 4 treatments.” NCT01359007 ↗ “docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.” NCT04649476 ↗ “Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)” NCT02052960 ↗ “Patients will apply 5% 5-Fluorouracil cream in a thin layer twice daily for 4 weeks on the treatment areas randomized to this treatment.” NCT06461442 ↗ “Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer” NCT02620800 ↗ “5-fluorouracil: 2400 mg/m2 intravenously for 46-48 hours or according to study Center clinical practice, D1, administered every 2 weeks” NCT06387810 ↗ “3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100)” NCT02181101 ↗ “The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.” NCT03322995 ↗ “A Phase I Study of Continuous Oral Administration of SCH 66336 and 5-Fluorouracil/Leucovorin (5FU/LV) in Patients With Advanced Cancer” NCT00003956 ↗ “RTOG 9704 randomized 538 patients after pancreatic resection to receive radiotherapy with either 5-fluorouracil (5-FU) or gemcitabine.” PMID 21625252 ↗ May 2011 “The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:” NCT02592395 ↗ “Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil.” PMID 26734580 ↗ Oct 2015 “Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion” NCT05077800 ↗ “mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.” NCT03250832 ↗ “5-FU (5-fluorouracil): 750mg/m², intravenous infusion, on day 1 to day 5, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment” NCT06952621 ↗ “Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.” NCT00509964 ↗ “The mFOLFOX6 regimen is: oxaliplatin, calcium leucovorin, 5-fluorouracil, bevacizumab, One cycle is every 2 weeks, lasting 2 cycles.” NCT06491355 ↗ “All patients received a 6-week induction course of docetaxel, carboplatin, infusional 5-fluorouracil, and gefitinib (250 mg daily).” PMID 19288572 ↗ May 2009 “The study drug is 5-Fluorouracil (Carac®); it will be used in this study to treat actinic keratoses on the face and anterior scalp.” NCT00696488 ↗ “5-fluorouracil 400 mg/m\^2 IV bolus on day 1, then 1200 mg/m\^2/dx2days(total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion” NCT04233151 ↗ “Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)” NCT00115765 ↗ “5-fluorouracil (5-FU) IV bolus (400 mg/m2) over 5 minutes on Day 1, followed by 5-FU (2400 mg/m2) IV continuously for 46-48 hours.” NCT06055179 ↗ “* 5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).” NCT01923987 ↗ “5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.” NCT01472016 ↗ “followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1” NCT02590367 ↗ “5-fluorouracil (5FU) and mitomycin C (MMC)-based chemoradiotherapy (CRT) is standard treatment for anal squamous cell carcinoma.” PMID 26597443 ↗ Nov 2015 “Each treatment regimen includes oxaliplatin 85 mg/m2, l-leucovorin 200 mg/m2, and 5-fluorouracil (5-FU) I.V. 400 mg/m2 on day 1” PMID 28237539 ↗ Jan 2017 “5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal” NCT00003596 ↗ “5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.” NCT02970916 ↗ “5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months).” NCT03085992 ↗ “5-Fluorouracil (5-FU) is an antimetabolite that can be used alone or with other chemotherapeutic agents to treat solid tumors.” NCT05599971 ↗ “5-Fluorouracil (5-FU) initially 400mg/m2 intravenous bolus followed by 2400mg/m2 continuous intravenous infusion over 46 hours” NCT06409637 ↗ “5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.” NCT04621370 ↗ “Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4.” NCT01670409 ↗ “5-Fluorouracil (5-FU) is an antimetabolite that can be used alone or with other chemotherapeutic agents to treat solid tumors.” NCT05599971 ↗ “Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care” NCT03088059 ↗ “Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma” NCT00053820 ↗ “* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours” NCT03563248 ↗ “Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin.” NCT05108428 ↗ “TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w” NCT05062005 ↗ “5-Fluorouracil 400 mg/m² via arterial bolus injection, followed by continuous arterial infusion of 2400 mg/m² over 23 hours” NCT07119931 ↗ “5-fluorouracil(5-FU) 2600mg/M2 administered via intravenous peripherally inserted central venous catheter(PICC) for 24 hour” NCT04384601 ↗ “Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)” NCT04643366 ↗ “docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m² and 5-FU (5-fluorouracil) 2600 mg/m², all i.v. on day 1 Q2W” NCT07059299 ↗ “Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles” NCT04136600 ↗ “Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan.” PMID 23493136 ↗ Mar 2013 “5-fluorouracil 400 mg/m\^2 bolus over 5-15 minutes then 2400 mg/m\^2 continual over 46-48 hours total dose IV on days 1-2” NCT01515787 ↗ “Drug: 5-fluorouracil 400 mg/sqm, day1,followed by 2400 mg/sqm iv infusion over 46\~48 h.Component of mFOLFOX6 or FOLFORI.” NCT05652894 ↗ “FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.” NCT04929223 ↗ “5-fluorouracil (chemical name: L01BC02; trade name: 5-Fluorouracil; formulation: concentrate for solution for injection)” NCT07472868 ↗ “TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5)” NCT05860868 ↗ “The chemotherapeutic agents include Doxorubicin, Gemcitabine , Paclitaxel, 5 Fluorouracil , Oxaliplatin, and Irinotecan.” NCT07254091 ↗ “5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2.” NCT00852228 ↗ “5-fluorouracil 400mg/m2 intravenous bolus injection, then continuous intravenous infusion of 1200mg/m2/day for 2 days.” NCT06363552 ↗ “5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1” NCT03130790 ↗ “mFOLFOX6 is a standard oxaliplatin-based chemotherapy regimen composed of oxaliplatin, leucovorin, and 5-fluorouracil.” NCT07175636 ↗ “5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous” NCT02885753 ↗ “5-fluorouracil 400 mg/m² intra-arterial bolus followed by 2400 mg/m² continuous intra-arterial infusion over 46 hours” NCT07522411 ↗ “FOLFOX-4 chemotherapy regimen consists of a combination of oxaliplatin with 5-fluorouracil (5-FU)/folinic acid (FA).” NCT01228734 ↗ “FOLFIRI regimen [leucovorin, 5-fluorouracil, and irinotecan] with/without bevacizumab on Days 1/15 of a 28-day cycle” PMID 38036720 ↗ Nov 2023 “The drugs that will be given by vein are OXALIPLATIN ("Oxali") plus 5-FLUOROURACIL and LEUCOVORIN ("5FU" and "LV").” NCT00059930 ↗ “FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin): 4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin” NCT02452853 ↗ “IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles.” NCT03788226 ↗ “FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W.” NCT06519578 ↗ “5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle.” NCT00555672 ↗ “Irinotecan Hydrochloride Liposome Injection (II) in combination with oxaliplatin, 5-fluorouracil, calcium folinate” NCT07238283 ↗ “5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles” NCT01270373 ↗ “irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks” NCT02423226 ↗ “irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks” NCT01736904 ↗ “5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.” NCT02023593 ↗ “5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump” NCT03523312 ↗ “IV 5-fluorouracil bolus (400 mg/m\^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m\^2) infusion over 48 hours” NCT00387387 ↗ “5-Fu(5 - Fluorouracil) (750 mg/m2/day) was administered as a 120-hour continuous intravenous infusion for 5 days” NCT02290145 ↗ “Pazopanib With 5-Fluorouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line Treatment in Advanced Gastric Cancer” NCT01503372 ↗ “5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer” NCT06887218 ↗ “5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.” NCT02251977 ↗ “Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2400 mg/m2 46-48 hour infusion” NCT04229004 ↗ “the intravenous equivalent of 5-Fluorouracil (5-FU) will be administered as a continuous intravenous infusion.” NCT00256841 ↗ “followed by 5-fluorouracil (5-FU) bolus (400 mg/m2) on Day 1 and 44-hour on continuous infusion (2400 mg/m2).” NCT04293419 ↗ “Or Bolus 5-FU regimen: 5-fluorouracil (5-FU) 400 mg/m2/day intravenously, administered on days 1-4 and 33-35.” NCT06758830 ↗ “Three-drug chemotherapy group, mFOLFIRINOX, including 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.” NCT06867146 ↗ “topical Actinic Keratosis treatments such as 5-FluoroUracil (5-FU) often lead to non-adhesion from patients” NCT04875026 ↗ “Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2” NCT03750669 ↗ “Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles” NCT06162650 ↗ “Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy” NCT05241574 ↗ “Systemic Chemotherapy Based on Oxaliplatin and 5-fluorouracil, Apatinib Plus Sintilimab for Metastasis ICC” NCT04682249 ↗ “Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil” NCT04380337 ↗ “The EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen)” PMID 25223462 ↗ Sep 2014 “5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT” NCT06662006 ↗ “5-Fluorouracil (5-FU): 400 mg/m² IV bolus, Day 1; then 1200 mg/(m²·day) × 2 days continuous IV infusion” NCT07204574 ↗ “5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W” NCT05684211 ↗ “5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2” NCT00364013 ↗ “folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1” NCT04230187 ↗ “5-Fluorouracil(600mg/m\^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m\^2/d) on days 1-5 and 29-33” NCT01126216 ↗ “5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1” NCT01501487 ↗ “Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days” NCT03114280 ↗ “Standard chemotherapy regimen (5-fluorouracil, leucovorin, and oxaliplatin), after chemoradiotherapy” NCT07622017 ↗ “IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days” NCT02572141 ↗ “5Fluorouracil protracted intravenous infusion (200 mg/m2 daily) plus Octreotide LAR (20 mg monthly)” NCT00953394 ↗ “5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1” NCT02510118 ↗ “5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1” NCT00819780 ↗ “400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV” NCT04389086 ↗ “with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks” NCT03246321 ↗ “5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1” NCT02529774 ↗ “5-Fluorouracil: 400mg/m2, D1, followed by 2400 mg/m2 as a continuous IV infusion over 46 hours,Q2W” NCT06871527 ↗ “Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen” NCT03720678 ↗ “5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion” NCT01219920 ↗ “5-fluorouracil (day 1; 400 mg/m(2) intravenous bolus, followed by 2,400 mg/m(2) as 46-h infusion)” PMID 25627002 ↗ Jan 2015 “with Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil” NCT03881111 ↗ “5-FU - 5-fluorouracil is used to treat cancer in combination with other chemotherapeutic agents” NCT06896188 ↗ “5-fluorouracil or capecitabine (a 5-FU prodrug) either alone or in combination with oxaliplatin” NCT05289076 ↗ “with 5-fluorouracil (5-FU) 1000mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles” NCT04747054 ↗ “5-Fluorouracil (5-FU) is an antimetabolite drug that is effective in the treatment of keloids.” NCT06175676 ↗ “5-Fluorouracil: 400mg/m2, D1, followed by 2400 mg/m2 as a continuous IV infusion over 46 hours” NCT06888037 ↗ “The PF regimen included 5 g/m2 5-fluorouracil via a continuous intravenous infusion over 120 h” NCT04398056 ↗ “followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2” NCT01085331 ↗ “5-Fluorouracil (2400mg/m2), leucovorin (200mg/m2), oxaliplatin (85mg/m2), docetaxel (50mg/m2).” NCT06279130 ↗ “5-Fluorouracil, 5-FU, NSC-19893; Methyl-CCNU, MeCCNU, NSC-95441; Vincristine, VCR, NSC-67574.” NCT00427570 ↗ “consisting of 5-fluorouracil (2400 mg/m2), irinotecan (180 mg/m2) and oxaliplatin (85 mg/m2).” NCT04594772 ↗ “FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle” NCT01632306 ↗ “5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.” NCT00277017 ↗ “Capecitabine or 5-fluorouracil Selection According to Polymorphisms in TS-3'UTR and ERCC1-118” NCT01071655 ↗ “association of 5-fluorouracil (5-FU), folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX)” NCT02967289 ↗ “5-fluorouracil (5-FU) 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days” NCT02563002 ↗ “docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 and 5-fluorouracil 2600 mg/m2” NCT04597294 ↗ “followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion” NCT01420874 ↗ “bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil” NCT05555901 ↗ “continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours)” NCT02503150 ↗ “FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil.” NCT03597581 ↗ “48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks” NCT04689347 ↗ “5-fluorouracil/folinic acid (5-FU/FA) in combination with either irinotecan or oxaliplatin” NCT01322178 ↗ “5-Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, Citrovorum Factor, CF, NSC-3590.” NCT00425152 ↗ “typical FOLFOX4 (Cam-FOLFOX4 group; infusional 5-fluorouracil, leucovorin and oxaliplatin)” PMID 34309846 ↗ Sep 2021 “This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).” NCT04683315 ↗ “mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.” NCT05111626 ↗ “5-Fluorouracil: 1000 mg/m²/day as a continuous infusion for 96 hours on days 1-4 and 29-32” NCT07425054 ↗ “5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle” NCT05047991 ↗ “bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6)” NCT05052801 ↗ “5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.” NCT01946074 ↗ “Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.” NCT03161522 ↗ “Cohorts Ph1b-D and D: Amivantamab+5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6)” NCT05379595 ↗ “Regimens containing cisplatin and 5-fluorouracil (5-FU) are widely adopted in the world.” NCT00632268 ↗ “HAIC (FOLFOX: oxaliplatin 85mg/m2, 5- fluorouracil 2500mg/m2, calcium folinate 400mg/m2)” NCT05753163 ↗ “Systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5- Fluorouracil (FOLFOX).” NCT00724503 ↗ “5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours” NCT06791512 ↗ “5-FLUOROURACIL 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks” NCT01358812 ↗ “Adjuvant chemotherapy (5-fluorouracil/capecitabine ± oxaliplatin 3 months to 6 months)” NCT06646445 ↗ “standard care FOLFOX-based (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy” PMID 25872567 ↗ Mar 2015 “Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).” NCT02638051 ↗ “* FOLFOX4:Oxaliplatin 85 mg/m2. l-Leucovorin 100 mg/m2 5-fluorouracil 400/600 mg/m2.” NCT02934464 ↗ “a chemotherapy regimen of oxaliplatin, 5-Fluorouracil (5-FU) and leucovorin (FOLFOX)” NCT01288339 ↗ “Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin.” NCT00332163 ↗ “Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin.” NCT00411450 ↗ “Combination of irinotecan, leucovorin, and 5-fluorouracil given via IV infusion Q2W.” NCT06252649 ↗ “modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) (nab-P/Gem-mFOLFOX)” PMID 38320486 ↗ Jan 2024 “Folfirinox(Systemic Chemotheray based on Oxaliplatin，5-fluorouracil and Irinotecan)” NCT04398927 ↗ “5-fluorouracil (500 mg/m2), epirubicin (90 mg/m2), and cyclophosphamide (500 mg/m2)” PMID 30413379 ↗ Nov 2018 “protracted 5-fluorouracil (5FU) infusion plus long-acting release (LAR) octreotide” NCT00953394 ↗ “5-fluorouracil (5-FU) 1600 to 2400 mg/m\^2 continuous infusion over 46 to 48 hours” NCT05609370 ↗ “the combination of 5-fluorouracil (5-FU), irinotecan and oxaliplatin (FOLFIRINOX)” NCT03487016 ↗ “Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart” NCT06737406 ↗ “leucovorin (LV) and 5-fluorouracil (5-FU) were used as the main treatment options” NCT06415851 ↗ “followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15” NCT02102789 ↗ “5-fluorouracil (400 mg/m² as bolus followed by 2400 mg/m2 as a 46-hour infusion)” PMID 29942666 ↗ Jun 2018 “immediately followed by 5- fluorouracil 2400 mg/m2 over 46 h continuous infusion” NCT06757244 ↗ “Patients received gemcitabine (gem) or 5-fluorouracil (5-FU) based chemotherapy.” PMID 40950337 ↗ Aug 2025 “5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 on day 1, q2w” NCT05842525 ↗ “5-fluorouracil 400 mg/m2 iv in bolus and 600 mg/m2 iv infusion over 22h: day 1-2” NCT02000050 ↗ “the low hENT1 (<50%) group received 5-fluorouracil plus folinic acid (5-FU/FA).” PMID 33795193 ↗ Mar 2021 “5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle” NCT05009953 ↗ “FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF” NCT00001338 ↗ “HAIC was adopted the FOFOLX6 program (Folinic acid+5-fluorouracil+Oxaliplatin).” NCT06311942 ↗ “2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin” NCT03366155 ↗ “5-fluorouracil 400 mg/m2 (IV push) 5-fluorouracil 2400 mg/m2 (Intravenous, IV)” NCT05262452 ↗ “infusions will consist of the drugs * 5-Fluorouracil * Irinotecan * Leucovorin” NCT03803553 ↗ “Start continuous infusion of 5-Fluorouracil at 800mg/m2/day x 5 days (120 hrs.” NCT01693718 ↗ “neoadjuvant mFOLFIRINOX (5-Fluorouracil, oxaliplatin, leucovorin, irinotecan)” NCT07671339 ↗ “Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)” NCT00551213 ↗ “standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU)” NCT03189719 ↗ “Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin” NCT03954704 ↗ “5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),” NCT03828227 ↗ “Eloxatin (oxaliplatin), leucovorin (folinic acid) and 5-Fluorouracil (5-FU)” NCT00265850 ↗ “5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG).” NCT00192075 ↗ “Oxaliplatin (Eloxatin), 5FU (5-Fluorouracil) and Leucovorin (Folinic Acid)” NCT00580073 ↗ “5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4” NCT02812641 ↗ “5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1” NCT03487939 ↗ “followed by 5-fluorouracil (5-FU) 2600 mg/m2 as a 24-h continuous infusion” NCT06731803 ↗ “Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w” NCT03044587 ↗ “followed by continuous infusion of 5-fluorouracil 2400 mg/m\^2 in 46 hours” NCT04687631 ↗ “5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles” NCT00807911 ↗ “5-Fluorouracil: 2400 mg/m², continuous intravenous infusion over 46 hours.” NCT07176182 ↗ “5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1” NCT03484195 ↗ “Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours.” NCT05375708 ↗ “5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1” NCT02271464 ↗ “bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU) (FOLFOX)” NCT02715531 ↗ “Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin” NCT04028167 ↗ “FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles” NCT00174655 ↗ “Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy” NCT00000758 ↗ “a regimen combining 5-fluorouracil (5-FU), folinic acid, and irinotecan” PMID 19826418 ↗ Oct 2009 “Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel” NCT06010303 ↗ “Isolated Hepatic Perfusion with Oxaliplatin and 5-Fluorouracil (5-FU)” NCT00557557 ↗ “* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2” NCT05534087 ↗ “FOLFIRI regimen (irinotecan, leucovorin, and 5-fluorouracil \[5-FU\])” NCT01133990 ↗ “5-Fluorouracil 2,400 mg/m2 IV over 46 hours via infusion pump at home” NCT03861702 ↗ “Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.” NCT04617821 ↗ “FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin)” PMID 32681477 ↗ Jul 2020 “400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2” NCT02758951 ↗ “and 5-fluorouracil 200 mg/m2 i.v. daily as continuous infusion (ECF)” NCT00301548 ↗ “5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab” PMID 31101691 ↗ May 2019 “5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab” PMID 31101691 ↗ May 2019 “Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin” NCT02355119 ↗ “5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1” NCT04781270 ↗ “2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy” NCT01312350 ↗ “simultaneous iv infusion of 5-fluorouracil (FU) + leucovorin (LV)” NCT02974556 ↗ “5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks” NCT02648425 ↗ “5-Fluorouracil (5-FU): 2400 mg/m², infused over 24 hours on Day 1” NCT07646717 ↗ “Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)” NCT04769908 ↗ “5-Fluorouracil 2400 mg/m² infused via arterial pump over 46 hours” NCT07024537 ↗ “the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil” NCT02909478 ↗ “5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous)” NCT07150403 ↗ “Modified Folfox; Oxaliplatin, 5-fluorouracil (5-FU), leucovorin” NCT05116891 ↗ “5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion” NCT01488552 ↗ “a 5-fluorouracil (5-FU) and Kenalog (triamcinolone) combination” NCT06362226 ↗ “5-fluorouracil (5-FU) 400 mg/m² IV bolus administered on day 1” NCT01327612 ↗ “5-fluorouracil (5-FU), Leucovorin, and oxaliplatin (mFOLFOX6)” NCT04662710 ↗ “EMB-01 + 5-Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI)” NCT07649655 ↗ “5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:” NCT01640405 ↗ “followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1” NCT06475352 ↗ “cisplatin (CDDP) plus 5-fluorouracil (5-FU) (the PF regimen)” NCT02969473 ↗ “5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid” NCT01274962 ↗ “5-fluorouracil bolus and continuous infusion every 2 weeks.” NCT07391163 ↗ “followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes” NCT02162563 ↗ “5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days.” NCT02439385 ↗ “5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25” NCT03558035 ↗ “FOLFIRI-3 = irinotecan + calcium folinate + 5-fluorouracil” NCT03288987 ↗ “5-fluorouracil \[50 mg/mL concentration; administered IV\]” NCT03798626 ↗ “cyclophosphamide-methotrexate-5-fluorouracil (CMF) therapy” PMID 23490655 ↗ Mar 2013 “such as cryotherapy, Imiquimod, or 5-fluorouracil (5-FU).” NCT00814528 ↗ “intravenous 5-fluorouracil, 800 mg/m2 per day on days 1-5” PMID 32437664 ↗ May 2020 “5\-Fluorouracil via IV, predetermined dosage per protocol” NCT04656041 ↗ “5-fluorouracil alone for patients with yp stage II or III” NCT03415763 ↗ “5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1” NCT02591667 ↗ “5-fluorouracil (5-fu) 400mg/m2 intravenous infusion day 1” NCT04131803 ↗ “5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes” NCT05400902 ↗ “treated with 5-fluorouracil (5-FU)/leucovorin or FOLFIRI” PMID 25361982 ↗ Oct 2014 “5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion)” NCT03043547 ↗ “5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion” NCT02028806 ↗ “FOLFIRI = irinotecan + calcium folinate + 5-fluorouracil” NCT03391934 ↗ “FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin” NCT06311916 ↗ “chemotherapies (docetaxel, cisplatin and 5-fluorouracil)” NCT04719988 ↗ “5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion” NCT06153368 ↗ “5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion” NCT04224402 ↗ “5-fluorouracil 400mg/m2, continuous infusion over 46-48h” NCT05353582 ↗ “Day 1-2: 3200 mg/m2 BSA of continuous 5-fluorouracil IV” NCT07472868 ↗ “5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion” NCT03484221 ↗ “5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion” NCT06389760 ↗ “5-fluorouracil \[5-FU\]: 2400 mg/m\^2 over 46-48 hours” NCT04068610 ↗ “5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)” NCT04418895 ↗ “5-Fluorouracil (5FU), leucovorin (LV), and irrinotecan” NCT01434069 ↗ “FOLFIRI (Irinotecan, 5-fluorouracil and Folinic Acid)” NCT02605044 ↗ “5-fluorouracil, epirubicin and cyclophosphamide [FEC]” PMID 29223479 ↗ Dec 2017 “mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil)” NCT07228832 ↗ “FOLFOX-4 (oxaliplatin, leucovorin and 5-fluorouracil)” NCT00349336 ↗ “FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel” NCT01206218 ↗ “800 mg/m\^2 5-fluorouracil \[5-FU\] administered IV” NCT03615326 ↗ “5-fluorouracil, oxaliplatin, Irinotecan, leucovorin” NCT04292743 ↗ “FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil” NCT00911170 ↗ “5-fluorouracil 1920 mg/m² 46-h intravenous infusion” NCT03530267 ↗ “5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4)” NCT03622827 ↗ “5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI)” NCT00780169 ↗ “IV infusional 5-Fluorouracil 2400 mg/m2 over 48h” NCT05194878 ↗ “HS-20093, Bevacizumab and 5-fluorouracil (5-FU)” NCT06825624 ↗ “all brands of 5-fluorouracil (5-FU) are allowed” NCT02363374 ↗ “all brands of 5-fluorouracil (5-FU) are allowed” NCT04230759 ↗ “TPF ( docetaxel, cisplatin and 5-fluorouracil )” NCT02944708 ↗ “5-Fluorouracil: 250 mg/m²/d continuous infusion” NCT00349076 ↗ “5-Fluorouracil 500 mg/m² i.v. body surface area” NCT00670878 ↗ “5-fluorouracil (5-FU; 2400 mg/m2 IV over 46 h)” PMID 42256682 ↗ May 2026 “Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles” NCT06054906 ↗ “5-fluorouracil (5-FU), leucovorin. oxaliplatin” NCT01322815 ↗ “systemic 5 fluorouracil (5FU), and leucovorin” NCT00244348 ↗ “5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks” NCT00735241 ↗ “5 Fluorouracil: 500mg/m2 - IV - Days 1 and 8” NCT00014222 ↗ “5-Fluorouracil : 2400mg/m2 infusion for 46-h” NCT05103020 ↗ “bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2” NCT05378919 ↗ “5-fluorouracil (5-FU) and leucovorin (IFL)” PMID 17216531 ↗ Jan 2007 “5-Fluorouracil, Leucovorin and Oxaliplatin” NCT00502567 ↗ “FP [5-fluorouracil [5-FU] plus cisplatin]” PMID 40473445 ↗ Jun 2025 “Chemotherapy: Cisplatin and 5fluorouracil” NCT02556762 ↗ “5-Fluorouracil (5-FU) 400mg/m2 IV PUSH D1” NCT01748851 ↗ “FP (5-fluorouracil \[5-FU\] + cisplatin)” NCT04210115 ↗ “5-fluorouracil 750-800mg/m2，iv，d1-d5，Q3W” NCT06463834 ↗ “5-fluorouracil + leucovorin + irinotecan” NCT01605344 ↗ “400 mg/m\^2 bolus 5-fluorouracil (5-FU)” NCT03829410 ↗ “PF regimen (cisplatin + 5-fluorouracil)” NCT03424291 ↗ “Leucovorin, 5-fluorouracil, Oxaliplatin” NCT05919264 ↗ “400 mg/m\^2 bolus 5-fluorouracil (5-FU)” NCT06936527 ↗ “Oxaliplatin, leucovorin, 5-fluorouracil” NCT00613080 ↗ “Carboplatin or Cisplatin+5-Fluorouracil” NCT02327078 ↗ “4. 5-fluorouracil: 2800 mg/m2, d1, q2w” NCT06643793 ↗ “epirubicin and 5-fluorouracil given IV” NCT00381706 ↗ “5-fluorouracil (5-FU)/leucovorin (LV)” NCT02448810 ↗ “5-Fluorouracil (5-FU) 400mg/m2 bolus” NCT05174169 ↗ “Folinic acid + 5-FU (5-Fluorouracil)” NCT01991873 ↗ “5-fluorouracil 500 mg/㎡ iv days 1,8” NCT01917578 ↗ “5-Fluorouracil 400 mg/m2 as a bolus” NCT01878422 ↗ “5 - Fluorouracil 400mg/m2 IV bolus” NCT05721872 ↗ “pentafluorouracil (5-fluorouracil)” NCT05183958 ↗ “5-fluorouracil-based chemotherapy” NCT01750918 ↗ “5-fluoro-uracil cream : Efudix®” NCT01059110 ↗ “cisplatin/5-fluorouracil (5-FU)” PMID 25707610 ↗ Jun 2015 “5-fluorouracil (5-FU)/cisplatin” PMID 28911091 ↗ Sep 2017 “5-Fluorouracil (5-FU) 500 mg/m²” NCT02339532 ↗ “5-fluorouracil (5Fu) 2400 mg/m2” NCT07284277 ↗ “5-Fluorouracil 2400mg/m2 civ48h” NCT06242418 ↗ “5-fluorouracil 750 mg/m2 (24 h)” NCT00785421 ↗ “5-FU (5-fluorouracil)-based CT” PMID 26487578 ↗ Oct 2015 “5-Fluorouracil or capecitabine” NCT06665087 ↗ “5-fluorouracil 1000 mg/m2 i.v.” NCT01262183 ↗ “5-Fluorouracil 500 mg/m² i.v.” NCT00847444 ↗ “5-fluorouracil 400mg/m2 iv d1” NCT03939962 ↗ “IV 5-Fluorouracil (500 mg/m2)” NCT01010854 ↗ “5-fluorouracil 500 mg/m\^2 IV” NCT00262067 ↗ “5-fluorouracil 600mg/m2 D1-D5” NCT03366883 ↗ “cisplatin plus 5-fluorouracil” NCT03623737 ↗ “5-Fluorouracil (5-FU; Efudex)” NCT01749956 ↗ “5-fluorouracil 2400 mg/m2 IV” NCT03483038 ↗ “Drug: 5-FU (5-fluorouracil)” NCT06943820 ↗ “Drug: 5-FU (5-fluorouracil)” NCT06897644 ↗ “followed by 5-fluorouracil” NCT05864105 ↗ “5-fluorouracil 1200mg/m2” NCT05872841 ↗ “Efudex (5-fluorouracil)” NCT00121511 ↗ “5-fluorouracil (5-FU)” NCT03909646 ↗ “5-Fluorouracil (5-FU)” NCT03109158 ↗ “5-FU (5-fluorouracil)” NCT04269369 ↗ “5-fluorouracil (5-FU)” NCT04126655 ↗ “5-FU (5-Fluorouracil)” NCT00382720 ↗ “5-Fluorouracil (5-FU)” NCT00215514 ↗ “5-fluorouracil (5-FU)” PMID 19457245 ↗ May 2009 “5-fluorouracil (5-FU)” NCT01088581 ↗ “5-fluorouracil (5-FU)” NCT02291289 ↗ “5-Fluorouracil (5-FU)” NCT00153998 ↗ “5 Fluorouracil (5FU)” NCT03070366 ↗ “5-Fluorouracil (5FU)” NCT01260415 ↗ “5-fluorouracil(5-FU)” NCT01658033 ↗ “Drug: 5-Fluorouracil” NCT01231802 ↗ “Drug: 5-Fluorouracil” NCT01726452 ↗ “Drug: 5Fluorouracil” NCT06461442 ↗ “5fluorouracil (5FU)” NCT00044785 ↗ “Drug: 5Fluorouracil” NCT05213312 ↗ “5-fluorouracil” NCT00064259 ↗ “5-fluorouracil” NCT05171166 ↗ “5 fluorouracil” NCT01726582 ↗ “5-Fluorouracil” NCT02128425 ↗ “5-fluorouracil” NCT00832299 ↗ “5-Fluorouracil” NCT03117972 ↗ “5-Fluorouracil” NCT04215731 ↗ |
| Known as | 5-Fluorouracil (5-FU) | “5-Fluorouracil (5-FU)” NCT01581307 ↗ |
| Known as | 5-Fluorouracil (5-FU; Efudex) | “5-Fluorouracil (5-FU; Efudex)” NCT01749956 ↗ |
| Known as | 5-fluorouracilo | “5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days” NCT00765011 ↗ |
| Known as | 5-fluoruracil | “Chemotherapy preferably CapOx (capecitabine + oxaliplatin) or FOLFOX (5-fluoruracil, leucovorin and oxaliplatin) will be combined with immunotherapy” NCT07000253 ↗13“5-fluoruracil(5-FU) 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion.” NCT03031444 ↗ “Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days” NCT04793932 ↗ “5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)” NCT02613650 ↗ “5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h” NCT04452461 ↗ “concurrent capecitabine or 5-fluoruracil (5-FU)” NCT02199236 ↗ |
| Known as | 5-Flurouracil | “5-Flurouracil (5-FU), leucovorin, and irinotecan; the combination is known as FOLFIRI.” NCT01183494 ↗ |
| Known as | 5-FU | “Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to...” NCT05959356 ↗1110“Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a...” NCT00548548 ↗ “This study is testing whether topical 5-fluorouracil (5FU) can be used as a patient-controlled adjuvant treatment for cervical precancer (CIN2/3) to be self-administered after...” NCT05413811 ↗ “Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for...” NCT03604965 ↗ “Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment...” NCT03301454 ↗ “It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400...” NCT01124630 ↗ “METHODS AND ANALYSIS: NET-02 is a UK, multicentre, randomised (1:1), parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan...” PMID 32029495 ↗ Feb 2020 “Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1,...” NCT02620423 ↗ “The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5...” NCT04083235 ↗ “The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as...” NCT00037180 ↗ “The treatment regimen was as follows: oral administration of sorafenib (400 mg twice daily for 28 days) combined with HAIC using CDDP (14-20 mg/m(2), on days 1 and 8) and 5-FU...” PMID 26734580 ↗ Oct 2015 “After completing 2 cycles of treatment, they were sequentially given liposomal irinotecan combined with 5-FU/LV, oxaliplatin (administered once every 2 weeks, with 4 weeks as...” NCT07208539 ↗ “Participants will undergo a modified schedule of EPIC (mEPIC) designed to maximize therapeutic benefit by exploiting the known pharmacokinetics and pharmacodynamics properties...” NCT05913674 ↗ “Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow...” NCT04543695 ↗ “In the early days when leucovorin (LV) and 5-fluorouracil (5-FU) were used as the main treatment options for patients with metastatic colorectal cancer (mCRC), the efficacy was...” NCT06491355 ↗ “This is a single arm phase II study, in which 2 cycles of chemotherapy (5FU/CDDP) and immunotherapy (durvalumab and tremelimumab) are administered every 3 weeks with concurrent...” NCT03377400 ↗ “This study will assess the safety and pharmacokinetics of adding dulanermin to Camptosar®/Erbitux® or the FOLFIRI regimen (Camptosar®, 5-FU, and leucovorin) plus bevacizumab...” NCT00671372 ↗ “FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil \[5-FU\], and 2400 mg/m\^2 continuous intravenous infusion 5-FU over 46 hours) will be...” NCT04446793 ↗ “For each dose of GOFL chemotherapy, intravenous infusion of gemcitabine at a fixed rate of 10 mg/m2/min will be immediately followed by a 2-hour intravenous infusion of...” NCT00149578 ↗ “Participants enrolled will receive QL1706 (5 mg/kg, Q3W, d1) + docetaxel (50 mg/m², Q3W, d1) + oxaliplatin (100 mg/m², Q3W, d1) + leucovorin (LV) (400 mg/m², Q3W, d1) +...” NCT07400315 ↗ “This randomized, double-blind, parallel-controlled, multicenter phase 3 study (NCT05074589) assessed the efficacy and safety of liposomal irinotecan HR070803 combined with...” PMID 39300077 ↗ Sep 2024 “The standard chemotherapy arm (Arm 1) will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV...” NCT02624999 ↗ “followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity...” NCT06509880 ↗ “FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2...” NCT00339183 ↗ “A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous...” NCT01333709 ↗ “We hypothesize that the addition of Eryaspase to FOLFIRINOX (5-fluorouracil \[5-FU\], leucovorin, irinotecan, and oxaliplatin) will be safe and demonstrate preliminary signs of...” NCT04292743 ↗ “The primary objective of this study is to determine whether S-1 increases overall survival when compared to 5-Fluorouracil (5-FU) in patients with metastatic pancreatic cancer...” NCT00602745 ↗ “oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2...” NCT02226380 ↗ “Fluropyrimidines (FPs), such as 5-Fluorouracil (5-FU) and Capecitabine, are cornerstone chemotherapy agents widely used in the treatment of various cancers, including...” NCT07158164 ↗ “Liposomal irinotecan (nal-IRI) combined with fluorouracil (5-FU)/leucovorin (LV) as a second-line treatment for biliary tract cancer (BTC) following progression on...” PMID 40147791 ↗ Mar 2025 “400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion)...” NCT02813096 ↗ “Cryotherapy is a treatment that uses extreme cold produced by liquid nitrogen to freeze and destroy abnormal cells, and 5-FU is a topical cream applied to the skin to treat...” NCT06461442 ↗ “Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2...” NCT00265850 ↗ “FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycles for up to 12...” NCT02923921 ↗ “Arm A will receive only systemic chemotherapy according to this scheme: Oxaliplatin 85 mg/m2, d1, over 2 h, Leucovorin 400 mg/m2, d1 i.v. over 2 h, 5-FU 400 mg/m2 in bolus and...” NCT05303714 ↗ “PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR...” NCT00002716 ↗ “Seventy colorectal cancer patients, from one academic and five community cancer centers, received the mFOLFOX6 regimen (5-FU 2,400 mg/m(2) over 46 hours every 2 weeks) with or...” PMID 25117066 ↗ Aug 2014 “irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or...” NCT01328171 ↗ “Administration of docetaxel 60 mg/m² on Day 1, Cisplatin 60 mg/m² after the end of the docetaxel infusion and 5-fluorouracil (5-FU) 600 mg/m²/day from Day 1 after the end of...” NCT00811447 ↗ “5-fluorouracil (5-FU) is an antimetabolite drug, used for several therapeutic purposes in dermatology, including premalignant and malignant lesions, keloid scars, vitiligo, and...” NCT07041749 ↗ “modified FOLFOX with Oxaliplatin 85 mg/m2 i.v. on day 1; Folinic Acid 400 mg/m2 i.v. on day 1; 5-FU 2,400 mg/m2 i.v. continuous infusion over 48 hours (no bolus!) on days 1 and...” NCT07176312 ↗ “Fluorouracil (5-FU) will be administered intravenously as a 400 mg/m2 IV bolus on days 1 and 15 followed by 2400 mg/m2 over 46-48 hours of continuous infusion on days 1-3 and...” NCT06328738 ↗ “A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic...” NCT00056030 ↗ “A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in...” NCT00423293 ↗ “TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on...” NCT00921531 ↗ “Cetuximab 500mg/m² + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or...” NCT02063529 ↗ “Bevacizumab 5mg/kg + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or...” NCT02350530 ↗ “This is a phase I study to investigate the safety and pharmacokinetics of weekly 5-fluorouracil (5-FU) administered as a bolus dose in children and young adults with recurrent...” NCT01498783 ↗ “Standard of care therapy consists of 6 - 12 two-week cycles of bevacizumab + FOLFOX (5-FU, leucovorin, oxaliplatin) followed by two-week cycles of bevacizumab + capecitabine...” NCT03050814 ↗ “the objective of this protocol is to use a triple therapy based on 5FU and oxaliplatin associated to irinotecan which is administered by hepatic intra-arterial route, loaded...” NCT01839877 ↗ “Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous...” NCT03985891 ↗ “Liposomal Irinotecan (Nal-IRI) Plus 5-fluorouracil and Leucovorin (5-FU/LV) Plus Oxaliplatin (NALIRIFOX) as First-Line Chemotherapy for Patients With Advanced Small Intestine...” NCT07060014 ↗ “In the experimental arm, patients will be treated with irinotecan 180 mg/m2 + leucovorin 400 mg/m2 at day 1 then 5-FU 400 mg/m2 bolus followed by 2400 mg/m2 continuous infusion...” NCT06501482 ↗ “Phase II Study of Oxaliplatin in Combination With 5-fluorouracil (5-FU) and Folinic Acid (FA) in Patients Who Have Failed First-line Treatment for Locally Advanced or...” NCT00782041 ↗ “Combination of the drug Taxotere together with a compound called 5-FU either as continuous infusion or in its oral form of a pill called "Xeloda" enhanced its anti cancer...” NCT00256841 ↗ “5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream...” NCT04926545 ↗ “Participants will undergo tumor harvest for TIL and then receive 2 to 3 cycles of pembrolizumab or pembrolizumab/platinum chemotherapy (cisplatin or carboplatin / 5-FU) as per...” NCT06236425 ↗ “During radiotherapy, patients either receive fluorouracil (5-FU) continuous infusion, 5-FU bolus IV and leucovorin calcium IV weekly, or a 5-day bolus schedule of 5-FU and...” NCT00003422 ↗ “5-Fluorouracil (5-FU) is a chemotherapeutic agent used in the treatment of many malignant tumors and it has been approved for topical use in the treatment of several...” NCT05513924 ↗ “followed by 5 Fluorouracil (5 FU), intravenous bolus, at a dose of 400 mg/m² on D1, followed by 5 Fluorouracil (5 FU) as a 46-hour continuous infusion at a dose of 2400 mg/m²...” NCT00467142 ↗ “The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day...” NCT06099951 ↗ “FOLFIRI regimen (irinotecan 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, and then 5-FU 2400 mg/m2 over 46 hours on Days 1 and 15 of each...” NCT05983367 ↗ “A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II)” NCT00025142 ↗ “The current use of anti-scarring agents such as 5 Fluorouracil (5FU), is a well established method employed by ophthalmologists to clinically reduce the postoperative scarring response.” NCT00607685 ↗ “NALIRIFOX is a chemotherapy regimen that includes liposomal irinotecan, oxaliplatin, 5-fluorouracil (5-FU), and leucovorin, administered intravenously in 10-12 cycles every two weeks.” NCT07173387 ↗ “mFOLFOX6 consisting of Folinic acid (Leucovorin) 400 mg/m2 (D,L racemic form) or 200 mg/m2 (L-isomer form [levo leucovorin]), 5-fluorouracil (5-FU) 2400 mg/m2 and Oxaliplatin 85 mg/m2” NCT05052099 ↗ “Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (VORINOSTAT)] With Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (FOLFIRI) for Advanced Upper Gastrointestinal Cancers” NCT00537121 ↗ “Chemotherapy regimen FULIRI: Irinotecan liposome 70 mg/m2; leucovorin CF 400 mg/m2, d1, iv drop; 5-FU 400 mg/m2, d1, iv drop; 5-FU 2400 mg/m2, d1, CIV 46-48h; repeated every 2 weeks.” NCT07515963 ↗ “5-fluorouracil (5FU) is an antimetabolite that has been demonstrated to have beneficial effects when injected into the subconjunctival space after glaucoma surgery (trabeculectomy).” NCT06745856 ↗ “5-Fluorouracil (5FU) is proven to be the most effective therapy in field directed treatment for AK, with Jansen et al. reporting a 1-year probability of treatment success of 74.7%.” NCT06499415 ↗ “Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks.” NCT03875781 ↗ “This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM) combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV).” NCT00176774 ↗ “The adjuvant chemotherapy treatment based on the use of fluoropyrimidine, especially 5-fluorouracil (5-FU) is the mainstay of the pharmacological treatment of colorectal cancer.” NCT03213444 ↗ “It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.” NCT07030283 ↗ “A Phase II Study of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), and Leucovorin (CF) in Patients With Metastatic Colorectal Carcinoma Previously Treated With Irinotecan (CPT-11)” NCT00016978 ↗ “Chemotherapy regimens based on fluorouracil (5-FU), such as CAPOX with a 3-week cycle or mFOLFOX6/FOLFIRI/FOLFOXIRI with a 2-week cycle, may be combined with targeted therapy.” NCT06794086 ↗ “Five per cent 5-fluorouracil (5-FU) cream is a well-established treatment for actinic keratosis (AK), and ingenol mebutate gel (IMB) is a novel topical field-directed therapy.” PMID 25727104 ↗ Feb 2015 “FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle” NCT03391843 ↗ “The primary purpose of this Phase I protocol is to develop an orally administered regimen of fluorouracil (5-FU) given with fixed doses of leucovorin (LV) and 776C85 (GW776)” NCT00001579 ↗ “Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated” NCT01839799 ↗ “Arm I: Patients receive docetaxel IV over 1 hour, immediately followed by cisplatin IV over 1 hour on day 1 and fluorouracil (5-FU) IV as a continuous infusion on days 1-5.” NCT00003888 ↗ “5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2” NCT03635021 ↗ “Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.” NCT02494973 ↗ “Docetaxel 50 mg/m² IV over 1 hour plus Oxaliplatin 85 mg/m² IV over 2 hours plus Folinic Acid 200 mg/m² IV over 1 hour plus 5-FU 2600 mg/m² IV over 24 hours every 2 weeks” NCT05504720 ↗ “Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).” NCT02834559 ↗ “After induction therapy, patients will continue with maintenance therapy using bevacizumab, PD-1 inhibitor, and 5-fluorouracil (5-FU), administered every 2 weeks (Q2W).” NCT06958419 ↗ “5-FU 400 mg/m² intravenous bolus on Day 1, followed by continuous intravenous infusion of 1200 mg/(m²·day) for 2 days (total dose 2400 mg/m², infused over 46-48 hours).” NCT07683403 ↗ “(Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging” NCT06197425 ↗ “Patients who decide to participate in the study will receive a chemotherapy drug called 5-Fluorouracil (5FU)through an intravenous catheter continuously over 12 weeks.” NCT00188266 ↗ “Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.” NCT02231086 ↗ “combination of gemcitabine, 5-fluorouracil (5-FU), and leucovorin (LV) in patients with unresectable or metastatic biliary tract or gallbladder adenocarcinoma (ACA).” PMID 15558814 ↗ Jan 2005 “FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h).” NCT04757363 ↗ “Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles” NCT05268510 ↗ “Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles” NCT04747054 ↗ “Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.” NCT05797467 ↗ “Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.” NCT05797077 ↗ “Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.” NCT05815082 ↗ “mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2 d1+5-FU 400mg/m2d1 /2400mg/m2 continuous intravenous injection (civ) for 46h” NCT06329947 ↗ “The purpose of this study is to evaluate the efficacy and the toxicity of lobaplatin, 5-fluorouracil (5-FU) and leucovorin in patients with esophageal carcinoma.” NCT01034683 ↗ “Here, we investigated the efficacy of calcipotriol, a topical TSLP inducer, in combination with 5-fluorouracil (5-FU) as an immunotherapy for actinic keratosis.” PMID 27869649 ↗ Nov 2016 “FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1” NCT02941562 ↗ “The combination of docetaxel, cisplatin, and 5-fluorouracil (5-FU) demonstrates high response rates in advanced gastric cancer, albeit with increased toxicity.” PMID 31138725 ↗ May 2019 “5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company.” NCT02017704 ↗ “The objective of this study was to evaluate the efficacy and safety of 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% as field-directed treatment of AK lesions.” PMID 27995485 ↗ Dec 2016 “A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer” NCT00192075 ↗ “The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.” NCT02826837 ↗ “Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3” NCT01489865 ↗ “Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week” NCT05665023 ↗ “Patients will receive ablative fractional laser (AFL)-assisted cisplatin+5-fluorouracil (5-FU) as a treatment for their cutaneous basal cell carcinoma (BCC).” NCT03541252 ↗ “Arm I: Patients receive fluorouracil (5-FU), recombinant alfa-2a interferon, hydroxyurea (HU), and filgrastim (granulocyte colony-stimulating factor; G-CSF).” NCT00003172 ↗ “Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion” NCT01888978 ↗ “mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2.” NCT02965248 ↗ “mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2.” NCT04370925 ↗ “Adjuvant chemotherapy consists of 6 cycles of 5FU/folinic acid and oxaliplatin (FOLFOX) every 2 weeks, or 4 cycles of capecitabine and oxaliplatin (CAPOX).” NCT07188025 ↗ “The aim of this randomized trial is to evaluate the potential benefit of a bitherapy with 5-fluorouracil (5-FU) and oxaliplatin as first line chemotherapy” NCT00126256 ↗ “PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10” NCT01522989 ↗ “Flurouracil (5FU) at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan” NCT03374852 ↗ “patients with metastatic PDAC who were previously treated with one prior line of therapy with 5-fluorouracil (5-FU) based or gemcitabine-based regimen.” NCT06625320 ↗ “5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;” NCT01763450 ↗ “If first-line chemotherapy based on gemcitabine, 5-FU-based regimen for second-line, If 5-FU-based regimen for first-line, gemcitabine for second-line.” NCT04677192 ↗ “mFOLFIRINOX- IV oxaliplatin 85 mg/m2; IV leucovorin 400 mg/m2; IV irinotecan 150 mg/m2; 5-FU 2400 mg/m2 by 46-hour infusion, per local standard of care” NCT07280377 ↗ “FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)” NCT02688803 ↗ “NALIRIFOX consists of 5-FU 2400 mg/m2 over 46 hours, liposomal irinotecan 50 mg/m2, and oxaliplatin 60 mg/m2, which would be given on Day 1 and Day 15” NCT07163273 ↗ “FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.” NCT00959647 ↗ “5-FU 400mg/m² injection, d1; Levofolic acid for injection at 200mg/m² and 5-FU at 2400mg/m² were mixed and infused simultaneously for 46 to 48 hours.” NCT07391618 ↗ “The choice of fluoropyrimidine (either 5-fluorouracil (5FU) or capecitabine) was decided by the treating physician and patient before randomisation.” PMID 19165196 ↗ Jan 2009 “consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.” NCT01611857 ↗ “5-FU, 400 mg/m2 administered as a bolus injection (iv push administered by hand) and then at 2400 mg/m2 administered as a iv infusion over 46 hours.” NCT04259944 ↗ “One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others Epirubicin, Cisplatin and 5-FU (ECF).” NCT01216644 ↗ “The combination chemotherapeutic regimen with irinotecan + 5-fluorouracil (5-FU)/leucovorin (LV) + oxaliplatin (FOLFIRINOX) is an effective choice” NCT03528785 ↗ “5-fluorouracil (5-FU) is a standard of care in frail/elderly patients with an unresectable colorectal adenocarcinoma (CRC) in first-line setting.” NCT07124884 ↗ “The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.” NCT00199797 ↗ “A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract” NCT00003175 ↗ “5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours.” NCT03343301 ↗ “Systemic chemotherapy traditionally used in the treatment of pancreatic cancer has included drugs such as gemcitabine or 5-fluorouracil (5-FU).” NCT01446458 ↗ “5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours” NCT03694522 ↗ “One of the most active treatment combinations is known as FOLFOX, which is a combination of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin.” NCT00478946 ↗ “This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.” NCT03042780 ↗ “Efficacy of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) in high-risk pediatric retinal detachment; randomized clinical trial.” PMID 38433191 ↗ Mar 2024 “mFOLFOX6 (oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 and 5FU (fluorouracil) 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous infusion)” NCT02648711 ↗ “Oxaliplatin 85 mg/m2 + Leucovorin 400 mg/m2 IV, followed by 5-FU 400 mg/m2 IV, followed 5-FU 2400 mg/m2 IV by continuous infusion over 46 hours” NCT01363843 ↗ “5-Fluorouracil (5-FU) 400 mg/m² given as a bolus and 2400 mg/m² continuous IV infusion over 46-48 hours on Day 1, 15 and 29 of a 42-day cycle.” NCT07680569 ↗ “Avastin (Anti-VEGF) and 5 fluorouracil(5FU) (antimetabolite) are medications that suppress the formation of VEGF and fibroblast growth factor.” NCT02530801 ↗ “bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP” NCT01540344 ↗ “After progression, only 40 to 45% of patients will receive a second line chemotherapy which will include 5-fluoro-uracil (5FU) and irinotecan” NCT04325425 ↗ “5-fluorouracil (5-FU)/folate, the standard of care for metastatic colorectal cancer (mCRC), have generated interest in optimizing the folate.” PMID 38059497 ↗ Jan 2024 “standard first-line leucovorin/5-FU/oxaliplatin (FOLFOX6)/bevacizumab (FOLFOX/BEV) every 2 weeks with (n = 51) or without (n = 52) pelareorep” PMID 29653857 ↗ Mar 2018 “Standard treatment of squamous cell carcinoma of the anus (SCCA)is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT).” PMID 37315583 ↗ Jun 2023 “5-FU was administered every 4 weeks during the first 5 days of each cycle as a continuous intravenous infusion at a dose of 1,000 mg/m\^2/d.” NCT00042510 ↗ “epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks” NCT00767377 ↗ “Chemotherapy regimens, include gemcitabine and 5-fluorouracil (5FU) but practices are highly heterogenous due to the low level of evidence.” PMID 41622055 ↗ Jan 2026 “5-fluorouracil (5-FU): 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles).” NCT01804790 ↗ “Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.” NCT03167112 ↗ “i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin\* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2” NCT03081143 ↗ “The regimen of mFOLFOX treatment includes, Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus on day 1” NCT05484024 ↗ “Assess the efficacy and safety of 5-fluorouracil (5FU) compared with saline, delivered using a tattoo machine, to repigment IGH lesions.” PMID 37011024 ↗ Apr 2023 “followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours” NCT02162563 ↗ “irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle” NCT02217020 ↗ “irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle” NCT03161574 ↗ “A Phase I Study of Continuous Oral Administration of SCH 66336 and 5-Fluorouracil/Leucovorin (5FU/LV) in Patients With Advanced Cancer” NCT00003956 ↗ “RTOG 9704 randomized 538 patients after pancreatic resection to receive radiotherapy with either 5-fluorouracil (5-FU) or gemcitabine.” PMID 21625252 ↗ May 2011 “5-fluoruracil(5-FU) 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion.” NCT03031444 ↗ “Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.” NCT04595266 ↗ “For SCCIS, topical treatment with 5-fluorouracil (5-FU) cream (a topical antineoplastic agent) is an established, off-label treatment” NCT04839731 ↗ “Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion” NCT05077800 ↗ “Patients will be randomized at enrollment to one of three arms: 5-Fluorouracil (5-FU) 5mg/0.1mL, bevacizumab 2.5mg/0.1mL, or placebo.” NCT03037736 ↗ “5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion” NCT01030042 ↗ “5-FU (5-fluorouracil): 750mg/m², intravenous infusion, on day 1 to day 5, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment” NCT06952621 ↗ “Participants will receive a 400 mg/m\^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m\^2 5 FU 46 hour i.v. infusion.” NCT01289821 ↗ “5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)” NCT02022033 ↗ “5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)” NCT02080221 ↗ “5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)” NCT02578732 ↗ “Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)” NCT00115765 ↗ “Interferon with continuous infusion 5-Fluorouracil (5-FU) regimens have shown response rates ranging from 0-43% in various cancers.” NCT01658813 ↗ “Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W” NCT03168607 ↗ “Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.” NCT04257461 ↗ “5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 to Day 4, repeated every 3 weeks.” NCT00612495 ↗ “This treatment will be followed by fluorouracil (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2” NCT02311439 ↗ “It consists of irinotecan, leucovorin, and fluorouracil (5-FU) administered sequentially over a 46-hour infusion period per cycle.” NCT07381309 ↗ “5-fluorouracil (5-FU) IV bolus (400 mg/m2) over 5 minutes on Day 1, followed by 5-FU (2400 mg/m2) IV continuously for 46-48 hours.” NCT06055179 ↗ “Patients (n = 68) received cetuximab weekly plus 3-week cycles of cisplatin/5-fluorouracil (5-FU) chemotherapy for up to 6 cycles.” PMID 24710768 ↗ Sep 2014 “Docetaxel in Combination With Cisplatin and 5-Fluorouracil (5-FU) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck” NCT00139269 ↗ “Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles” NCT00145769 ↗ “Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w” NCT05193292 ↗ “followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1” NCT02590367 ↗ “HAIC: Irinotecan liposome 30 mg/m2, leucovorin 200 mg/m2, 5-FU 200 mg/m2 bolus followed by continuous infusion of 5-FU 1200 mg/m2” NCT06375642 ↗ “5-fluorouracil (5FU) and mitomycin C (MMC)-based chemoradiotherapy (CRT) is standard treatment for anal squamous cell carcinoma.” PMID 26597443 ↗ Nov 2015 “5-FU 400 mg/m² , bolus injection, followed by 1200 mg/(m²·d) continuous IV for 2 days (total dose 2400 mg/m² over 46 - 48 hours)” NCT06959693 ↗ “Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles” NCT05621499 ↗ “Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32” NCT04230759 ↗ “5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours” NCT00976768 ↗ “Fluorouracil (5-FU) is administered by continuous IV infusion for 4 days (on days 1-4 and 29-32) after completion of cisplatin.” NCT00003118 ↗ “5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.” NCT02970916 ↗ “5-Fluorouracil (5-FU) is an antimetabolite that can be used alone or with other chemotherapeutic agents to treat solid tumors.” NCT05599971 ↗ “followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus injection and 5-FU continuous IV infusion of 2400 mg/m2 over 46 to 48 hours.” NCT07011576 ↗ “5-Fluorouracil (5-FU) initially 400mg/m2 intravenous bolus followed by 2400mg/m2 continuous intravenous infusion over 46 hours” NCT06409637 ↗ “Irinotecan 150mg /m2, d1, oxaliplatin 85mg/m2, d1, 5-Fu, 2400mg/m2, pumped continuously for 46 hours and repeated for 14 days” NCT06048146 ↗ “Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.” NCT03825861 ↗ “* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours” NCT03563248 ↗ “NALIRIFOX: Oxaliplatin 85 mg/m2, D1; Liposomal irinotecan 60 mg/m2, D1; LV 200 mg/m2; 5-FU 2400 mg/m2, Infusion for 48 hours” NCT07622771 ↗ “5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion” NCT01640782 ↗ “fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle)” NCT04587128 ↗ “Fluorouracil (5FU) is still considered the most active antineoplastic agent in the treatment of advanced colorectal cancer.” PMID 3049954 ↗ Oct 1988 “5-fluorouracil(5-FU) 2600mg/M2 administered via intravenous peripherally inserted central venous catheter(PICC) for 24 hour” NCT04384601 ↗ “Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.” NCT05141721 ↗ “5-FU: 2400 mg/m2 IV over the course of 48 hours (or until the infusion is complete) on days 1 and 15 of every 4-week cycle.” NCT05851924 ↗ “Folinic Acid 400 mg/m2, iv, d1, q2w, 5-FU 400 mg/m2 IV bolus d1 then 5-FU 2400 mg/m2 IV infusion over 46 to 48 hours, q2w.” NCT06841679 ↗ “5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.” NCT04642287 ↗ “docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m² and 5-FU (5-fluorouracil) 2600 mg/m², all i.v. on day 1 Q2W” NCT07059299 ↗ “A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously.” NCT05469061 ↗ “Perioperative docetaxel 50mg/m2；oxaliplatin 85 mg/m2; 5Fu 2.4g/m2 civ 48 hours; repeated every 2 weeks; total of 8 cycles” NCT03961841 ↗ “fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis” NCT06047379 ↗ “pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy versus placebo plus cisplatin and 5-FU chemotherapy” NCT03881111 ↗ “This treatment is followed by a continuous intravenous infusion of 2400 mg/m2 5-FU over a 46-hour period every 2 weeks.” NCT06384560 ↗ “OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours” NCT01161316 ↗ “Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks” NCT06253611 ↗ “Standard treatment includes the chemotherapy combination of 5-FU, Leucovorin and Oxaliplatin (FOLFOX) with bevacizumab.” NCT01516216 ↗ “Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)” NCT00915850 ↗ “5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion, q2w;” NCT05074966 ↗ “Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion” NCT05417386 ↗ “CAF: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Fluorouracil, 5-FU, NSC-19893; followed by TMX.” NCT00929591 ↗ “5-fluorouracil (5-FU) has been considered the most effective systemic agent for managing advanced colorectal cancer.” PMID 16098249 ↗ Jul 2005 “5-FU bolus - Starting dose 400 mg/m2 (administered after LV on Day 1, then) 5-FU infusion - Starting dose 2400 mg/m2” NCT02726334 ↗ “The drugs that will be given by vein are OXALIPLATIN ("Oxali") plus 5-FLUOROURACIL and LEUCOVORIN ("5FU" and "LV").” NCT00059930 ↗ “Immediately after the completion of the CF infusion, patients receive an IV bolus injection of fluorouracil (5-FU).” NCT00003446 ↗ “Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes.” NCT00941655 ↗ “Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²” NCT04570943 ↗ “Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.” NCT04068610 ↗ “followed by a bolus of 5-FU 400 mg/m2 within 15 min and 46-hour infusion of 5-FU 2400 mg/m2 on day 1 every 2 weeks” NCT03415763 ↗ “Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.” NCT02862561 ↗ “Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.” NCT02873520 ↗ “Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days.” NCT03671252 ↗ “Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).” NCT04120701 ↗ “HAIC with FOLFOX: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.” NCT05535647 ↗ “5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump” NCT03523312 ↗ “Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles)” NCT02012062 ↗ “fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles” NCT01703390 ↗ “day 1: intravenous 5-FU 2600 mg/m² inserted through a peripherally inserted central catheter (PICC) for 24 hours” NCT06459921 ↗ “5-Fu(5 - Fluorouracil) (750 mg/m2/day) was administered as a 120-hour continuous intravenous infusion for 5 days” NCT02290145 ↗ “5-FU 400mg/m2 intravenous push on days 1 and 15, followed by 1200mg/(m2∙d) × 2d continuous intravenous infusion” NCT07362836 ↗ “5-FU+l-LV: 5-FU 500mg/m2, l-LV 250mg/m2, weekly administration for 6 times, repeated three times every 8 weeks.” NCT00190515 ↗ “rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h)” NCT04747951 ↗ “Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy.” NCT06005324 ↗ “Chemotherapy (standard of care with first line therapy of base of 5-FU with either oxaliplatin or irinotecan).” NCT07044362 ↗ “Modified FOLFOX-4 regimen consists of 85 mg/m2 oxaliplatin plus 200 mg/m2 LV and 5-FU 400 mg/m2 bolus on day 1” PMID 38238055 ↗ Jan 2024 “5-FU 400 mg/m\\(\^2\\), IV, d1, followed by 2400 mg/m\\(\^2\\), continuous intravenous infusion over 46 hours.” NCT06650332 ↗ “5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase.” NCT06097416 ↗ “5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.” NCT02178709 ↗ “Or Bolus 5-FU regimen: 5-fluorouracil (5-FU) 400 mg/m2/day intravenously, administered on days 1-4 and 33-35.” NCT06758830 ↗ “followed by 5-fluorouracil (5-FU) bolus (400 mg/m2) on Day 1 and 44-hour on continuous infusion (2400 mg/m2).” NCT04293419 ↗ “FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -\> 2400mg/m2 46hrs continuous” NCT01269229 ↗ “The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU.” NCT03691441 ↗ “5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.” NCT02581215 ↗ “Patients received radiotherapy with concurrent 5-Fluororuracil (5-FU)/Capecitabine and Oxaliplatin, and RHT.” PMID 33805731 ↗ Mar 2021 “5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g.” NCT04796948 ↗ “Chemotherapy regimen consisting of irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin” NCT07325214 ↗ “Drug: Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.” NCT05412589 ↗ “Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.” NCT05009069 ↗ “topical Actinic Keratosis treatments such as 5-FluoroUracil (5-FU) often lead to non-adhesion from patients” NCT04875026 ↗ “Combination treatment may include: 5FU/LFA, capecitabine, oxaliplatin, irinotecan, bevacizumab, aflibercept” NCT07213570 ↗ “5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours.” NCT01121848 ↗ “The regimen consists of docetaxel, 50 mg/m2, 5-FU, 2400 mg/m2, and leucovorin, 240 mg/m2 on days 1 and 15.” NCT00270543 ↗ “and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion” NCT01347645 ↗ “5-FU 400 mg/m2 IVP，d1,1200 mg/m2/d×2 days（Total:2400 mg/m2，Continuous intravenous infusion,46\~48 hours,）” NCT05362617 ↗ “5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT” NCT06662006 ↗ “followed by 5-FU 400 mg/m2 intravenous bolus and then 5-FU 2400 mg/m2 intravenous infusion over 46 hours” NCT03597581 ↗ “mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.” NCT05968326 ↗ “Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression.” NCT05988814 ↗ “30 Gy or 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)” NCT06563479 ↗ “oral capecitabine (Xeloda) versus 5-fluorouracil (5-FU), in combination with intravenous (IV) cisplatin” NCT02563054 ↗ “5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus” NCT05378867 ↗ “oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals” NCT03443661 ↗ “5-FU will be administered as an intravenous infusion(IV) every 3 weeks on Day 1-5 of each 21-day cycle.” NCT07700667 ↗ “400 mg/m2 bolus 5-fluorouracil (5-FU) given on day 1 followed by 2400 mg/m2 5-FU infusion over 46-48 h” PMID 34446053 ↗ Aug 2021 “Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle” NCT06172205 ↗ “Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.” NCT06736717 ↗ “followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion” NCT00101894 ↗ “These drugs include Cisplatin or Oxaliplatin and 5-fluorouracil (5 FU) in combination with Docetaxel.” NCT04931420 ↗ “5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks” NCT06978400 ↗ “mFOLFOX6: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2:” NCT05332002 ↗ “Patients receive fluorouracil (5-FU) IV continuously and leucovorin calcium (CF) IV on days 1 and 2.” NCT00046995 ↗ “5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.” NCT04167007 ↗ “Then, 5-Fu (750 mg/m2/day) was administered as a 120-hour continuous intravenous infusion for 5 days” NCT02285530 ↗ “5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles” NCT04136600 ↗ “5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1” NCT02510118 ↗ “participants will self-administer 2 g of 5FU cream intravaginally once every two weeks for 12 doses” NCT07545746 ↗ “5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1” NCT00819780 ↗ “5-Fu 400mg/m\^2, arterial infusion, lasting 3 hours (d1), and fluorouracil 2400 mg/m\^2 for 24-48h;” NCT06363825 ↗ “Afterwards depth will be decreased to 1.5mm and 5 FU will be rubbed on the lesion before this step.” NCT07398807 ↗ “Fluorouracil 5-FU continuous infusion: 400mg/m2 on Dand then 2400mg/m2 for 46h of each 21 day cycle” NCT07267806 ↗ “Then, 5-Fu(750 mg/m2/day) was administered as a 120-hour continuous intravenous infusion for 5 days” NCT02285543 ↗ “Patient will then receive 5-FU: 1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days” NCT01671488 ↗ “receiving Sunitinib in Addition to 5-FU, Folinic Acid and Irinotecan (FOLFIRI) as 1st Line Therapy” NCT00806663 ↗ “Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.” NCT00776724 ↗ “Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion” NCT04145193 ↗ “5-Fluorouracil (5-FU) 400 mg/m² IV bolus + 5-FU 2400 mg/m² continuous IV infusion over 46 hours.” NCT06225843 ↗ “hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.” NCT05519410 ↗ “5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles” NCT00524303 ↗ “RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC” NCT02426450 ↗ “5-FU - 5-fluorouracil is used to treat cancer in combination with other chemotherapeutic agents” NCT06896188 ↗ “IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.” NCT02826486 ↗ “5-Fluorouracil (5-FU) is an antimetabolite drug that is effective in the treatment of keloids.” NCT06175676 ↗ “Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve time to tumor progression” PMID 15677624 ↗ Jan 2005 “1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50” NCT02205008 ↗ “association of 5-fluorouracil (5-FU), folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX)” NCT02967289 ↗ “post-surgery combination chemotherapy in the abdomen with fluorouracil (5-FU) and paclitaxel.” NCT00004547 ↗ “5-Fluorouracil, 5-FU, NSC-19893; Methyl-CCNU, MeCCNU, NSC-95441; Vincristine, VCR, NSC-67574.” NCT00427570 ↗ “followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion” NCT01420874 ↗ “5-fluorouracil (5-FU) 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days” NCT02563002 ↗ “* Bolus 5FU 400 mg/m² , followed by * Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks” NCT02969681 ↗ “5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours” NCT00752570 ↗ “5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours” NCT05360732 ↗ “including fluorouracil (5-FU), cisplatin, doxorubicin, mitomycin, leucovorin and interferon” NCT03164382 ↗ “48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks” NCT04689347 ↗ “modified regimen of leucovorin, bolus and infusional 5-fluorouracil [5-FU], and oxaliplatin” PMID 30592991 ↗ Dec 2018 “FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)” NCT03022734 ↗ “followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion.” NCT05476796 ↗ “5-Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, Citrovorum Factor, CF, NSC-3590.” NCT00425152 ↗ “leucovorin calcium (CF) IV followed by fluorouracil (5-FU) IV (1 hour before radiotherapy)” NCT00002523 ↗ “sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36” NCT01123811 ↗ “5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1” NCT05008809 ↗ “5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours” NCT06521866 ↗ “oxaliplatin 85mg/m2 + leucovorin 400mg/m2 + 5-fu 400mg/m2 + 5-fu 2400mg/m2 46h iv.drip Q3W” NCT07192185 ↗ “Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days.” NCT03210389 ↗ “5-FU, 400mg/m²IV Day1, then 1200 mg/(m².d) ×2 days (total 2400 mg/m² ,IV over 46-48 hours)” NCT07021950 ↗ “5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29” NCT03018418 ↗ “5-FU 400 mg/m², intravenous bolus, Day 1; followed by 2400 mg/m² infusion over 46-48 hours” NCT07604909 ↗ “Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.” NCT02795988 ↗ “5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle” NCT05047991 ↗ “Fluorouracil (5-FU), leucovorin and oxaliplatin are considered traditional chemotherapies” NCT00116506 ↗ “5-FU has been the mainstay of chemotherapeutic agents for gastrointestinal malignancies.” NCT00201305 ↗ “Bleomycin and 5-fluorouracil (5-FU) are widely used in various dermatological disorders.” PMID 38256469 ↗ Jan 2024 “OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h” NCT01605305 ↗ “5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles” NCT01232374 ↗ “5-FU bolus 400 mg / m² Day1 followed by continuous 5-FU 2400 mg / m2 total over 46 hours” NCT02352337 ↗ “admixing with 5-FU 2,000 mg/m2 and leucovorin (folinic acid) 300 mg/m2, day 1 and day 8” NCT00384878 ↗ “* 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2” NCT04151277 ↗ “FOLFIRI (Leucovorin 200 mg/m2、5-FU 2800 mg/m2、Irinotecan 180 mg/m2) plus target therapy” NCT06826092 ↗ “OPC-18: 500IU \* 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery” NCT00524498 ↗ “FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion” NCT05593328 ↗ “FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion” NCT06106308 ↗ “5-Flurouracil (5-FU), leucovorin, and irinotecan; the combination is known as FOLFIRI.” NCT01183494 ↗ “5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days” NCT00890305 ↗ “5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion” NCT02202928 ↗ “Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV” NCT06360354 ↗ “5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion” NCT02215837 ↗ “Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2.” NCT03529279 ↗ “a chemotherapy regimen of oxaliplatin, 5-Fluorouracil (5-FU) and leucovorin (FOLFOX)” NCT01288339 ↗ “Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy” NCT03772132 ↗ “5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.” NCT01383538 ↗ “5-FU, 2,400 mg/m² IV once every two weeks over 46-48 hours administered via infusion” NCT05825066 ↗ “self-administered intravaginal 5% 5-Fluorouracil (5FU) cream as an adjuvant therapy” PMID 39980670 ↗ Feb 2025 “with fluorouracil (5-FU) IV bolus 1 hour into the infusion once weekly for 6 weeks.” NCT00023751 ↗ “The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.” NCT00825669 ↗ “followed by 5-FU, epirubicin, and cyclophosphamide (FEC) every 3 weeks for 4 cycles” NCT00110695 ↗ “protracted 5-fluorouracil (5FU) infusion plus long-acting release (LAR) octreotide” NCT00953394 ↗ “5-fluorouracil (5-FU) 1600 to 2400 mg/m\^2 continuous infusion over 46 to 48 hours” NCT05609370 ↗ “5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion” NCT04185883 ↗ “5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours” NCT03485027 ↗ “5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days” NCT03254394 ↗ “5-FU 400mg/m2, day 1, then 1200mg/ (m2•d) ×2days(total 2400mg/m2, infusion 46-48h)” NCT05468177 ↗ “5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion” NCT05179889 ↗ “leucovorin (LV) and 5-fluorouracil (5-FU) were used as the main treatment options” NCT06415851 ↗ “Evaluate the pharmacokinetics (PK) profile of fluorouracil (5-FU) and irinotecan.” NCT04535401 ↗ “Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart” NCT06737406 ↗ “Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU” NCT04687163 ↗ “either Fluorouracil (5-FU) or Capecitabine or other Standard of Care Chemotherapy” NCT05315830 ↗ “Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin” NCT00440310 ↗ “5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks)” NCT06275958 ↗ “cisplatin 80 mg/m\^2 IV Q3W, and 5-FU 600 mg/m\^2/day IV infusion on Days 1 to 5.” NCT04813523 ↗ “followed by 5-FU (2400 mg/m\^2) continuous infusion over 46 hours, every 3 weeks.” NCT07312422 ↗ “Patients received gemcitabine (gem) or 5-fluorouracil (5-FU) based chemotherapy.” PMID 40950337 ↗ Aug 2025 “Arm I: Patients receive fluorouracil (5-FU) IV over 24 hours weekly for 6 weeks.” NCT00002722 ↗ “5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h” NCT05263219 ↗ “5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2” NCT01543412 ↗ “5-FU administered as bolus followed by additional administration as IV infusion.” NCT05052801 ↗ “5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h” NCT05582278 ↗ “* 5-FU bolus 400mg/m2 (up to 15 min infusion) * 5-FU 2400 mg/m2 IV over 46 hours” NCT05848739 ↗ “bolus application 5-FU 400 mg/m\^2 followed by 46h infusion of 5-FU 2400 mg/m\^2” NCT01827553 ↗ “5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump” NCT02620800 ↗ “oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)” NCT02658214 ↗ “5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle” NCT05009953 ↗ “Ongericimab, Toripalimab, Bevacizumab, Oxaliplatin, Calcium folinate, 5-FU, Q2W” NCT07106034 ↗ “DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles.” NCT03744208 ↗ “Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)” NCT03618758 ↗ “Escalation treatment (5FU + irinotecan + oxaliplatin [FOLFIRINOX] for 6 months)” NCT07340567 ↗ “1000 mg/m ²/day 5-FU administered as a 96-hour C.I. starting on week 1, day 1.” NCT01063075 ↗ “5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2” NCT04348045 ↗ “fluorouracil [5-FU], leucovorin [LV], and irinotecan/nanoliposomal irinotecan” PMID 41187298 ↗ Nov 2025 “BOLD-100 +/- Folinic acid (leucovorin), Fluorouracil (5-FU), and Oxaliplatin.” NCT04421820 ↗ “using the chemotherapy regimen of Oxaliplatin + Irinotecan Liposome + 5-FU/LV” NCT07020468 ↗ “5-FU: 2400 mg/m2 ,ivgtt over 46h, D29-30, every 6 weeks for a treatment cycle” NCT07235930 ↗ “5-FU: 2400 mg/m2 ,ivgtt over 46h, D29-30, every 6 weeks for a treatment cycle” NCT06393166 ↗ “irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf” NCT00479583 ↗ “In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU” NCT05057663 ↗ “Nanoliposomal Irinotecan (Nal-Iri) and 5-Fluorouracil/Folinic Acid (5-FU/FA)” PMID 36056179 ↗ Sep 2022 “5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours.” NCT02592395 ↗ “Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin” NCT03954704 ↗ “plus 5-fluorouracil (5-FU) as a third- or subsequent-line treatment for mCRC” PMID 35282086 ↗ Jan 2022 “5-FU 400 mg/m² IV bolus + 2400 mg/m² continuous infusion over 46h (Days 2-3)” NCT07053150 ↗ “Optional adjuvant regimens include FOLFOX, CapeOX, 5-FU+LV, or Capecitabine.” NCT06520683 ↗ “5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),” NCT03828227 ↗ “OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks.” NCT03185988 ↗ “5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1” NCT02358863 ↗ “5-FU: 2400 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).” NCT06993025 ↗ “folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin (mFOLFOX6)” NCT02102022 ↗ “followed by 5-fluorouracil (5-FU) 2600 mg/m2 as a 24-h continuous infusion” NCT06731803 ↗ “Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w” NCT03044587 ↗ “5-Fluoro-uracil (5-FU) IV 2,400 mg/m²/h will be administered over 46 hours” NCT02539537 ↗ “5Fu bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours” NCT03584711 ↗ “5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1.” NCT01661088 ↗ “Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate” NCT04126655 ↗ “Oxaliplatin (Eloxatin), 5FU (5-Fluorouracil) and Leucovorin (Folinic Acid)” NCT00580073 ↗ “irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion” NCT07446322 ↗ “450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation” NCT01613469 ↗ “5-FU is a chemotherapy that causes the death of proliferating tumor cells.” NCT04329221 ↗ “fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes” NCT05712356 ↗ “5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion” NCT05004350 ↗ “Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours” NCT04516681 ↗ “receive S-1 plus cisplatin (CS group) or 5-FU plus cisplatin (CF group).” PMID 26439700 ↗ Oct 2015 “Eloxatin (Oxaliplatin) + Leucovorin (Folinic acid) + 5-FU (Fluorouracil)” NCT02574663 ↗ “Gemcitabine+Capecitabine or Oxaliplatin+lrinotecan+Calcium folinate+5-FU” NCT07114666 ↗ “Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU” NCT04667351 ↗ “Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy” NCT00000758 ↗ “and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles” NCT03574324 ↗ “5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours” NCT00881504 ↗ “a regimen combining 5-fluorouracil (5-FU), folinic acid, and irinotecan” PMID 19826418 ↗ Oct 2009 “or fluorouracil (5-FU), a potent inhibitor of fibroblast proliferation” NCT04710719 ↗ “5-FU 2400 mg/m2 as a continuous IV infusion over 46 hours, from day 1.” NCT07616362 ↗ “Drug: 5-FU 2400mg/m\^2, intravenous infusion, d1-2, 14 days per cycle.” NCT07309289 ↗ “Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.” NCT04617821 ↗ “Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, CF, NSC-3590.” NCT00002570 ↗ “5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)” NCT03069950 ↗ “5-fluorouracil(5-FU) 2400-2800 mg/sqm 46-48 hours continuous infusion” NCT05382442 ↗ “bolus injection of 5FU and subsequent continuous 5FU 46-hour infusion” NCT01964287 ↗ “5-FU 400 mg/m² IV bolus, then 5-FU 2400 mg/m² continuous IV over 46 h” NCT07328087 ↗ “followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour” NCT02142322 ↗ “5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours” NCT04611724 ↗ “5-fluorouracil (5FU) does not require the same transport into cells.” NCT01411072 ↗ “经验总结 • 5‐氟尿嘧啶（5‐FU）、奥沙利铂和拉帕替尼联合放疗的新辅助疗法用于局部人表皮生长受体2阳性食管胃交界处腺癌患者是安全的。” PMID 28765502 ↗ Aug 2017 “Investigator's Choice of Chemotherapy: nal-IRI + 5-FU/LV, AG, or S-1” NCT07689539 ↗ “5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively” NCT01060501 ↗ “* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion” NCT04089150 ↗ “For non-cisplatin candidates, carboplatin/5fu will be administered.” NCT05307939 ↗ “5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2” NCT05948072 ↗ “5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion” NCT02375672 ↗ “a 10-min bolus of 400 mg/m2 5-FU, and 2400 mg/m2 5-FU over 46 hours” NCT07061080 ↗ “Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours.” NCT03084809 ↗ “Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks” NCT02486601 ↗ “5FU 400mg/m2/day with Leucovorin 20mg/m2/day IV on day 1 and day29” NCT01269216 ↗ “Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles” NCT01230476 ↗ “HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8.” NCT00275951 ↗ “5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port” NCT06632717 ↗ “folinic acid [FA] + fluorouracil [5-FU] + oxaliplatin [mFOLFOX-6]” NCT01111604 ↗ “5-Fluorouracil (5-FU): 2400 mg/m², infused over 24 hours on Day 1” NCT07646717 ↗ “5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours” NCT01704703 ↗ “FOLFIRI (Irinotecan, leucovorin, 5FU I.V.bolus and 5FU I.V. c.i.)” NCT01853813 ↗ “5-FU 225mg/m2 was delivered as a continuous infusion on days 1-38” NCT00139633 ↗ “D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses)” NCT00313872 ↗ “5-FU: 2400 mg/m2 i.v. over 46h /14 days on D1-3, 15-17, and 29-31” NCT05679050 ↗ “plus Cisplatin, CDDP, NSC-119875; Fluorouracil, 5-FU, NSC-19893.” NCT00002631 ↗ “On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin.” NCT00826800 ↗ “5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1” NCT06603376 ↗ “5-FU is given as a continuous intravenous infusion over 2 days.” NCT04361708 ↗ “a 5-fluorouracil (5-FU) and Kenalog (triamcinolone) combination” NCT06362226 ↗ “Modified Folfox; Oxaliplatin, 5-fluorouracil (5-FU), leucovorin” NCT05116891 ↗ “F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite” NCT01523457 ↗ “5-FU: 2400 mg/m² continuous intravenous infusion over 46 hours;” NCT07469956 ↗ “5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle” NCT04130854 ↗ “INJ. 5FU 750 MG/M2 IV THROUGH INFUSION PUMP OVER 24 HOURS D 1-4” NCT06737822 ↗ “continuous fluorouracil (5-FU) 200 mg/m(2)/day (protracted IV)” PMID 21943032 ↗ Sep 2011 “5-fluorouracil (5-FU) 400 mg/m² IV bolus administered on day 1” NCT01327612 ↗ “5-FU 2400mg/m\^2, continuous intravenous infusion for 46 hours” NCT06368063 ↗ “Drugs:FOLFOX regimen: oxaliplatin, calcium folinate, and 5-FU.” NCT05833126 ↗ “For Arms M1 and E1: 5-FU or capecitabine will be administered.” NCT06731478 ↗ “followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1” NCT06475352 ↗ “5-fluorouracil(5-FU), calcium leucovorin(LV), and bevacizumab” NCT06643793 ↗ “③5-FU: 2400 mg/m2, continuous intravenous infusion, Q2W, d1-2” NCT06699459 ↗ “5-Fu combined with irinotecan or oxaliplatin standard regimen” NCT03412994 ↗ “* 5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1” NCT02591030 ↗ “5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days” NCT03193814 ↗ “cisplatin (CDDP) plus 5-fluorouracil (5-FU) (the PF regimen)” NCT02969473 ↗ “5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid” NCT01274962 ↗ “5-fluorouracil (5-FU) has been successful in stable vitiligo” PMID 42319271 ↗ Jun 2026 “5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours” NCT03186326 ↗ “5-FU bolus + infusions (400 mg/m\^2) on days 1, 2, 15 and 16” NCT00439517 ↗ “A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2” NCT00885885 ↗ “5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1” NCT05926206 ↗ “epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）” NCT01053390 ↗ “FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}” NCT02319304 ↗ “irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)” NCT00967616 ↗ “fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus” NCT03874026 ↗ “Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²” NCT01581840 ↗ “continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h” NCT04835064 ↗ “One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.” NCT01276379 ↗ “mFOLFIRINOX: - Oxaliplatin; Leucovorin; Irinotecan and 5-FU” NCT05354817 ↗ “Continuous intravenous infusion of fluorouracil (CIV 5-FU)” NCT02497157 ↗ “5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2” NCT02749136 ↗ “bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)” NCT00625651 ↗ “5-fluorouracil (5-fu) 400mg/m2 intravenous infusion day 1” NCT04131803 ↗ “Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy” NCT00261703 ↗ “5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2” NCT05081687 ↗ “b)5-FU 1000 mg/m2, d1-4, continuous pumping intravenously” NCT06364384 ↗ “5-FU 2400 mg/m² as a continuous IV infusion over 46 hours” NCT06278545 ↗ “day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours” NCT01460589 ↗ “treated with 5-fluorouracil (5-FU)/leucovorin or FOLFIRI” PMID 25361982 ↗ Oct 2014 “oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV” NCT05083247 ↗ “5FU, leucovorin, oxaliplatin, irinotecan and bevacizumab” NCT03401294 ↗ “fluorouracil (5-FU) IV over 46 hours beginning on day 1” NCT00062426 ↗ “5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks” NCT01364376 ↗ “Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w” NCT05751265 ↗ “5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion” NCT06241599 ↗ “Includes oxaliplatin, irinotecan, leucovorin, and 5-FU.” NCT06648434 ↗ “5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV” NCT01571024 ↗ “5-Fluorouracil (5FU), leucovorin (LV), and irrinotecan” NCT01434069 ↗ “FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])” NCT00615056 ↗ “Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours” NCT05257993 ↗ “5-FU (2400 mg/m2/day continuous IV infusion over 48 h)” NCT05986227 ↗ “5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2” NCT00202787 ↗ “FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)” NCT06792695 ↗ “traditional administration of 5FU-Mitomycin C with RT” NCT01285778 ↗ “FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)” NCT07204574 ↗ “Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU” NCT04155671 ↗ “5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35;” NCT03561142 ↗ “total 5-FU 2400mg/m², iv gtt (continuous for 48h), d1” NCT07070713 ↗ “fluorouracil (5-FU) IV over 22 hours on days 1 and 2” NCT00006479 ↗ “fluorouracil (5-FU) IV over 22 hours on days 1 and 2” NCT00006468 ↗ “Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium.” NCT05124002 ↗ “5-FU: 400 mg/m2 IV bolus injection for over 5 minute” NCT04810585 ↗ “5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin” NCT05751850 ↗ “5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)” NCT04447092 ↗ “DNA Intercalators (Capecitabine, 5-FU, gemcitabine)” NCT02299999 ↗ “oxaliplatin folinic acid irinotecan 5FU oxaliplatin” NCT02676349 ↗ “* 5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours” NCT01688336 ↗ “cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5” NCT00910117 ↗ “5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4)” NCT03622827 ↗ “Fluorouracil/Leucovorin, Oxaliplatin (5-FU/LV, OX)” NCT07074353 ↗ “5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)” NCT02843191 ↗ “5-FU: 2400 mg/m² IV over 48 hours infusion (Day 1)” NCT06575127 ↗ “patients will be treated with gemcitabine or 5-FU.” NCT02486497 ↗ “5-fluorouracil (5-FU) 700 mg/m2 daily (day 14-16)” NCT00147147 ↗ “Fluorouracil (5-FU) plus carboplatin or cisplatin” NCT02723955 ↗ “5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI)” NCT00780169 ↗ “followed by 5-FU 2400 mg/m\^2 IV over 46-48 hours” NCT01821612 ↗ “fluorouracil (5-FU) IV continuously over 96 hours” NCT00003596 ↗ “5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1” NCT04416854 ↗ “FOLFIRI includes folic acid, 5-FU and irinotecan.” NCT06855849 ↗ “fluorouracil (5-FU) with leucovorin calcium (CF)” NCT00008060 ↗ “Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes” NCT01646554 ↗ “5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w” NCT01486992 ↗ “follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1” NCT02284529 ↗ “Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)” NCT00259402 ↗ “5-5-flourouracil (5-FU) 1000 mg/m\^2 of BSA/day” NCT04747470 ↗ “5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3” NCT05462496 ↗ “5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W” NCT03686254 ↗ “5 FU (mg/m2) continuous infusion, over two days” NCT00200200 ↗ “* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,” NCT03959293 ↗ “5-fluorouracil (5-FU), leucovorin. oxaliplatin” NCT01322815 ↗ “Leucovorin + Fluorouracil (5-FU) + Oxaliplatin” NCT00599924 ↗ “5-FU 400 mg/m² IV bolus given over 2-4 minutes” NCT02173990 ↗ “5FU bolus: 400 mg/m² per 10-minute IV infusion” NCT06278545 ↗ “5-FU 225 mg/m2/day 5 weeks during radiotherapy” NCT00259363 ↗ “systemic 5 fluorouracil (5FU), and leucovorin” NCT00244348 ↗ “5-FU 2,400 mg/m2 for 46 h continuous infusion” NCT01640444 ↗ “Drug 5-FU 400 mg/m2（D1，iv），2400 mg/m2 (48±4h)” NCT04835142 ↗ “5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle” NCT05070104 ↗ “concurrent fluorouracil (5-FU) and cisplatin” NCT00003642 ↗ “oxaliplatin+lrinotecan+calcium folinate+5-FU” NCT07594964 ↗ “Fluorouracil (5FU) bolus 400 mg/m2 iv day 1” NCT05527782 ↗ “ZW25 plus fluorouracil (5-FU) and cisplatin” NCT03929666 ↗ “Standard 5-fluorouracil (5-FU) chemotherapy” NCT01652482 ↗ “400 mg/m2 5-fluorouracil (5-FU) by IV bolus” NCT00724503 ↗ “5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h” NCT03591705 ↗ “Folinic Acid, 5-FU, Oxaliplatin, Irinotecan” NCT05466799 ↗ “5-FU：2400 mg/m2, i.v.for over 46 hours, q2w” NCT05522738 ↗ “Folinic acid, 5-FU, Irinotecan, Oxaliplatin” NCT06079346 ↗ “followed by 5-FU i.v. infusion for 48 hours” NCT01370876 ↗ “Experimental group:docetaxel,cisplatin,5-FU” NCT03196869 ↗ “5-fluorouracil (5-FU) 800 mg/m2 (Days 1-5)” PMID 37489066 ↗ Jul 2023 “bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2” NCT05378919 ↗ “5-fluorouracil (5-FU) and leucovorin (IFL)” PMID 17216531 ↗ Jan 2007 “over 5-fluorouracil (5-FU) and oxaliplatin” PMID 25979230 ↗ May 2015 “5-FU (400 mg/m2, IV bolus on D1-3, D29-31)” NCT02167321 ↗ “5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h” NCT06402708 ↗ “5-FU (400mg/m2), intravenous infusion, D1” NCT06154538 ↗ “fluorouracil plus leucovorin (5-FU + LV)” PMID 37535876 ↗ Aug 2023 “5-fluorouracil (5-FU) 400 mg/m² IV bolus” NCT02129257 ↗ “Subjects will receive Cisplatin plus 5FU” NCT00460265 ↗ “Hour + 2: 5-FU bolus 400 mg/m2, IV bolus” NCT01895257 ↗ “5-FU bolus IV of 400 mg/m² during 10 min” NCT04188145 ↗ “5-FU: 2400 mg/m², 46 h IV infusion on d1” NCT07004413 ↗ “400 mg/m\^2 bolus 5-fluorouracil (5-FU)” NCT03829410 ↗ “400 mg/m\^2 bolus 5-fluorouracil (5-FU)” NCT06936527 ↗ “5-FU (5-Fluorouracile)-treated patients” NCT02484677 ↗ “5-Fluorouracil (5-FU) + Leucovorin (LV)” NCT00090025 ↗ “5-FU 2400 mg/m² continuous 46h infusion” NCT06890624 ↗ “5-FU/leucovorin (2400 mg/m2, 400 mg/m2)” NCT05363007 ↗ “FOLFIRI (5-FU, irinotecan, leucovorin).” NCT02482441 ↗ “5-FU: 2400 mg/m2, 46-48h i.v., on day 1” NCT04495088 ↗ “FEC: 5FU 500mg/m2 intravenous bolus D1” NCT00525759 ↗ “fluorouracil (5-FU) 400 mg/m² IV bolus” NCT07437287 ↗ “fluorouracil (5-FU) 400 mg/m² IV bolus” NCT06529718 ↗ “fluorouracil (5-FU) 400 mg/m² IV bolus” NCT07359456 ↗ “fluorouracil (5-FU) 400 mg/m² IV bolus” NCT06846346 ↗ “5-fu 1300 mg/㎡ ivgtt maintain for 48hr” NCT00868816 ↗ “leucovorin 200 mg/m² + 5-FU 2800 mg/m²” NCT02942563 ↗ “Using 5-FU, Oxaliplatin, and Docetaxel” NCT04699994 ↗ “5-Fu 1 g/m\^2 on Days 1, 8, 15, and 22” NCT05497739 ↗ “mFOLFOX (5-FU+Oxalipatin+folinic acid)” NCT05065957 ↗ “adjuvant 5-FU and oxaliplatin (FOLFOX)” NCT02974556 ↗ “5FU continu 2000 mg/m² during 46 hours” NCT02827201 ↗ “Fluorouracil (5-FU) 42-48-hr infusion” NCT06518538 ↗ “5-fluorouracil (5-FU) 400mg/m2, day 1” NCT01523431 ↗ “Standard chemotherapy: Cisplatin+5-FU” NCT04146402 ↗ “Oxaliplatin plus Leucovorin plus 5-FU” NCT02845908 ↗ “Docetaxel+Irinotecan+5-FU+LV (1 pat.)” NCT01379482 ↗ “5-FU 2600 mg/m2 as a 24 hour-infusion” NCT06978062 ↗ “* 5-FU 2400 mg/m2 as 46 hour infusion” NCT03468335 ↗ “5-FU: 400 mg/m2 iv, 2400 mg/m2 civ46h” NCT01322178 ↗ “Folinic acid + 5-FU (5-Fluorouracil)” NCT01991873 ↗ “a 46-hour infusion 5-FU 2400 mg/m\^2” NCT01085331 ↗ “5-Fluorouracil (5-FU) 400mg/m2 bolus” NCT05174169 ↗ “5-FU 2.4g/m2 IV infusion for 46h, D1” NCT06151262 ↗ “infusional 5-FU, LV, and bevacizumab” NCT05329103 ↗ “* 5-FU 2600 mg/m², d1, d15, d29, d43” NCT02581462 ↗ “I.V. bolus 5-Fluorouracil (5-FU): 0” NCT03164655 ↗ “5-fluorouracil (also known as 5-FU)” NCT00040391 ↗ “5-FU (1200 mg/m²/day IV for 2 days)” NCT06207981 ↗ “5-FU 2400~3200 mg/m² cont. inf. 48h” NCT05201430 ↗ “5-FU 2000 mg/m2 as 24 hour infusion” NCT03331640 ↗ “Intravaginal 5-Fluorouracil (5-FU)” NCT05362955 ↗ “fluorouracil/leucovorin (5-FU/CF)” NCT00002896 ↗ “5-FU 500mg/m2/d, IV infusion d1-5” NCT01845675 ↗ “Bolus 5FU 400 mg/m² , followed by” NCT03015675 ↗ “5-FU via continuous IV infusion.” NCT00251355 ↗ “cisplatin + 5-fluorouracil (5FU)” NCT07026474 ↗ “400 mg/m\^2 5-Fluorouracil (5FU)” NCT06109467 ↗ “followed by 5-FU 2400 mg/m2 46 h” NCT06899477 ↗ “5-FU, leucovorin and oxaliplatin” NCT03692429 ↗ “5-FU, leucovorin and oxaliplatin” NCT04991948 ↗ “Bolus 5FU 400 mg/m², followed by” NCT00479752 ↗ “5% 5-fluorouracil (5-FU) powder” NCT07401277 ↗ “Fluorouracil (5-FU) 400mg/m2 IV” NCT03838406 ↗ “5-fluorouracil (5-FU)/cisplatin” PMID 28911091 ↗ Sep 2017 “5-Fluorouracil (5-FU) 500 mg/m²” NCT02339532 ↗ “high-dose 5-fluorouracil (5-FU)” NCT00155883 ↗ “5-fluorouracil (5Fu) 2400 mg/m2” NCT07284277 ↗ “5-FU, folinic acid, oxaliplatin” NCT01508000 ↗ “5-FU 400 mg/m² bolus at 3 hours” NCT07618546 ↗ “irinotecan, 5-FU and leucovorin” NCT01571284 ↗ “oxaliplatin,leucovorin and 5-FU” NCT03048123 ↗ “5-FU 400 mg/m2 IV bolus (day 1)” NCT03174405 ↗ “5-FU (5-fluorouracil)-based CT” PMID 26487578 ↗ Oct 2015 “5% 5-fluorouracil (5-FU) cream” NCT02281682 ↗ “5-FU 1000mg/m2 IVF for 24hours” NCT01283204 ↗ “Oxaliplatin, Irinotecan, 5-FU.” NCT02148549 ↗ “5-FU: 2400 mg/m² over 46 hours” NCT03719924 ↗ “5-FU 2400 mg/m² cont. inf. 46h” NCT04170530 ↗ “5-FU bolus day 1 every 14 days” NCT03904043 ↗ “5-Fluorouracil (5-FU) Plus LV” NCT00378716 ↗ “Fluorouracil, 5-FU, NSC-19893” NCT00002476 ↗ “Fluorouracil, 5-FU, NSC-19893” NCT00002692 ↗ “Fluorouracil, 5-FU, NSC-19893” NCT00002496 ↗ “Oxaliplatin, Leucovorin, 5-FU” NCT07543471 ↗ “5-FU 400 mg/m² bolus on day 1” NCT01315990 ↗ “5-FU: 2400mg/m2 ivgtt 46h q2w” NCT05669092 ↗ “Low dose Fluorouracil or 5FU” NCT01905150 ↗ “Drug: 5-fluorouracile (5-FU)” NCT02640365 ↗ “fluorouracil (5-FU) IV bolus” NCT00066846 ↗ “5-FU; Fluorouracil Injection” NCT03563157 ↗ “4. 5 FU, 400 mg/m2, IV bolus” NCT03603834 ↗ “5-FU: 1000mg/m2, Day1-3, Q3W” NCT06081582 ↗ “Drug: 5-fluorouracil (5-FU)” NCT07554521 ↗ “Drug: 5-Fluorouracil (5-FU)” NCT01286818 ↗ “Drug: 5-Fluorouracil (5-FU)” NCT06370754 ↗ “Drug: 5-fluorouracil (5-FU)” NCT07043400 ↗ “Drug: 5-Fluorouracil (5-FU)” NCT02008656 ↗ “Drug: 5-Fluorouracil (5-FU)” NCT01376453 ↗ “Drug: 5-Fluorouracil (5-FU)” NCT06469944 ↗ “Drug: 5-Fluorouracil (5-FU)” NCT06941857 ↗ “MMC and fluorouracil (5-FU)” PMID 19643599 ↗ Jul 2009 “5-FU (600 mg/m2 IV day 1-5)” NCT01133678 ↗ “5-FU 750 mg/m2/d c.i. d 1-4” NCT01181401 ↗ “5-Fu 400mg/m2 iv D1,2,15,16” NCT00813137 ↗ “5-FU：400mg/m2，IV，d1，d15，d29” NCT06452602 ↗ “Drug: 5Fluorouracil (5-FU)” NCT03197571 ↗ “NSC-3590 5-FU Fluorouracil” NCT00002783 ↗ “Drug: 5-Fluorouracil (5FU)” NCT00773695 ↗ “5-FU 400 mg/m² bolus day 1” NCT03688230 ↗ “Fluorouracil (5-FU): Q2W;” NCT07047560 ↗ “5-Fluorouracil (5-FU), IV” NCT06648525 ↗ “Drug: Fluorouracil [5-FU]” NCT02720068 ↗ “5-FU: 2400 mg/sqm, 46h-iv” NCT02363374 ↗ “* 5FU : 400 mg/m2 (bolus)” NCT03879109 ↗ “Drug: Fluorouracil (5FU)” NCT05526924 ↗ “Xeloda+ OXA or OXA+ 5-FU” NCT02777437 ↗ “- 5-FU 800 (-1000) mg/m²” NCT02128243 ↗ “5-fluorouracil \[5-FU\]” NCT01133990 ↗ “5-FU 400 mg/m2 IV bolus” NCT00673673 ↗ “Irinotecan IV + 5-FU IV” NCT02866903 ↗ “5-FU 400 mg/m2 bolus d1” NCT01310478 ↗ “5- Fluorouracil (5-FU)” NCT00337389 ↗ “fluorouracil (5-FU) IV” NCT00002696 ↗ “5-FU bolus 400 mg/m\^2” NCT03806309 ↗ “5-Fluorouracil (5-FU)” NCT03169738 ↗ “5-Fluorouracil (5-FU)” NCT05647122 ↗ “5-Fluorouracil (5-FU)” NCT02051868 ↗ “5-fluorouracil (5-FU)” NCT00705016 ↗ “5-fluorouracil (5-FU)” PMID 26911408 ↗ Feb 2016 “5-Fluorouracil (5-FU)” NCT03855384 ↗ “5-Fluorouracil [5-FU]” NCT03374254 ↗ “5-fluorouracil (5-FU)” NCT00381706 ↗ “5-fluorouracil (5-FU)” NCT00612586 ↗ “5-fluorouracil (5-FU)” PMID 19457245 ↗ May 2009 “5-Fluorouracil (5-FU)” NCT00215514 ↗ “5-fluorouracil (5-FU)” NCT06172036 ↗ “5-Fluorouracil (5-FU)” NCT00368329 ↗ “5-Fluorouracil (5-FU)” NCT07069712 ↗ “5-fluorouracil (5-FU)” NCT02735239 ↗ “5-fluorouracil (5-FU)” NCT06901531 ↗ “5-Fluorouracil (5-FU)” NCT03169790 ↗ “5-fluorouracil (5-FU)” NCT00697905 ↗ “5-FU (5-fluorouracil)” NCT04269369 ↗ “5-Fluorouracil (5-FU)” NCT00112918 ↗ “5-fluorouracil (5-FU)” NCT07256782 ↗ “5-fluorouracil (5-FU)” NCT02291289 ↗ “5-fluorouracil (5-FU)” NCT00401323 ↗ “5-fluorouracil (5-FU)” NCT01515787 ↗ “5-fluorouracil (5-FU)” NCT01088581 ↗ “5-FLUOROURACIL (5-FU)” NCT00988897 ↗ “5-fluorouracil (5-FU)” NCT03184870 ↗ “5-Fluorouracil (5-FU)” NCT06131840 ↗ “5-FU 400mg/m² push d1” NCT05797883 ↗ “5-Fluorouracil (5FU)” NCT01260415 ↗ “Fluorouracil or 5-FU” NCT04553692 ↗ “5Fluorouracil (5-FU)” NCT00122460 ↗ “5 Fluorouracil (5FU)” NCT05251038 ↗ “5-fluorouracil (5FU)” NCT02551159 ↗ “5-FU 400 mg/m2 IV d1” NCT01044420 ↗ “Fluorouracil (5-FU)” NCT04241185 ↗ “fluorouracil (5-FU)” NCT00003001 ↗ “Fluorouracil (5-FU)” NCT06509906 ↗ “Fluorouracil (5-FU)” NCT02083653 ↗ “fluorouracil (5-FU)” NCT00052910 ↗ “Fluorouracil (5-FU)” NCT03783442 ↗ “5-FU (fluorouracil)” NCT00217737 ↗ “Fluorouracil (5-FU)” NCT06733038 ↗ “5fluorouracil (5FU)” NCT00044785 ↗ “Fluorouracil (5-FU)” NCT04379596 ↗ “5-FU (fluorouracil)” NCT00291785 ↗ “fluorouracil (5FU)” NCT01077739 ↗ “Fluorouracil (5FU)” NCT04428333 ↗ “5-FU; Fluorouracil” NCT03563170 ↗ “Fluorouracil 5-FU” NCT06851507 ↗ “* 5FU: 2400 mg/m2” NCT02514278 ↗ “* 5FU, infusional” NCT03251612 ↗ “TP negative: 5-FU” NCT01453257 ↗ “5FU 2400 mg/m\^2” NCT03703063 ↗ “5-FU 2,000 mg/m2” NCT05066802 ↗ “5-FU：400 mg/m2” NCT05239650 ↗ “Drug: 5 - FU” NCT07700667 ↗ “Drug: 5-FU” NCT03279289 ↗ “Drug: 5-FU” NCT03872947 ↗ “Drug: 5-FU” NCT02641873 ↗ “* 5FU” NCT03070366 ↗ “5-FU” NCT01858025 ↗ “5-FU” NCT01959139 ↗ “5-FU” NCT00058474 ↗ “5-FU” NCT00002551 ↗ “5-FU” NCT01212822 ↗ “5-FU” NCT07532902 ↗ “5FU” NCT05628038 ↗ |
| Known as | 5-FU (5-fluorouracil) | “5-FU (5-fluorouracil)” NCT01516216 ↗ |
| Known as | 5Fluorouracile | “5-fluorouracile (D1) H+3: 400mg/m² IV infusion over 15min” NCT04392479 ↗ |
| Known as | Adrucil | “Adrucil, fluorouracil” NCT02046538 ↗1“Fluorouracil/Adrucil” NCT02741570 ↗ |
| Known as | Adrucil, fluorouracil | “Adrucil, fluorouracil” NCT02046538 ↗ |
| Known as | Carac | “Carac® (Fluorouracil) Cream” NCT02616601 ↗ |
| Known as | Efudex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00121511 ↗ |
| Known as | Efudex, 5-FU | “Efudex, 5-FU” NCT00847912 ↗ |
| Known as | Five-Fluorouracil | “Five-Fluorouracil (FU) is an antitumor agent blocks DNA synthesis by inhibition of pyrimidine and thymidine.” NCT07041749 ↗ |
| Known as | fluorouraci | “fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel” NCT02483767 ↗ |
| Known as | Fluorouracil (5-FU) | “Fluorouracil (5-FU)” NCT02568046 ↗5“Fluorouracil (5-FU)” NCT01571024 ↗ “Fluorouracil ; 5-FU” NCT01834963 ↗ “Fluorouracil: 5-Fu” NCT01642771 ↗ |
| Known as | Fluorouracil Injection | “5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g.” NCT04796948 ↗1“LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）” NCT04088604 ↗ |
| Known as | Fluorouracilo | “Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the...” NCT02246127 ↗ |
| Known as | Fluouracil | “Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes.” NCT00941655 ↗ |
| Known as | flurouracil | “The standard chemotherapy arm (Arm 1) will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV...” NCT02624999 ↗2“Flurouracil (5FU) at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan” NCT03374852 ↗ “Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2” NCT03504423 ↗ |
| Known as | FOLFIRI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04259944 ↗ |
| Known as | FOLFIRINOX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06714604 ↗ |
| Known as | Folfox4 plus recombinant human endostatin (Endostar) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00813137 ↗ |
| Known as | FOLFOX6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01605305 ↗ |
| Known as | FUra | “This protocol will evaluate the activity of 5-Fluorouracil (FUra) given as a 1 hour infusion in combination with leucovorin (LV) and interferon IFN alpha-2a in patients with...” NCT00001428 ↗ |
| Known as | infusional fluorouracil | “patient with colon cancer patients were randomly assigned to 3 and 6 months of modified FOLFOX6 (mFOLFOX6: infusional fluorouracil, leucovorin, and oxaliplatin) or capecitabine...” PMID 29620995 ↗ Apr 2018 |
| Known as | MMP with 5-FU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02904564 ↗ |
| Known as | NSC-19893 | “CAF: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Fluorouracil, 5-FU, NSC-19893; followed by TMX.” NCT00929591 ↗7“5-Fluorouracil, 5-FU, NSC-19893; Methyl-CCNU, MeCCNU, NSC-95441; Vincristine, VCR, NSC-67574.” NCT00427570 ↗ “5-Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, Citrovorum Factor, CF, NSC-3590.” NCT00425152 ↗ “Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, CF, NSC-3590.” NCT00002570 ↗ “plus Cisplatin, CDDP, NSC-119875; Fluorouracil, 5-FU, NSC-19893.” NCT00002631 ↗ “Fluorouracil, 5-FU, NSC-19893” NCT00002476 ↗ “Fluorouracil, 5-FU, NSC-19893” NCT00002692 ↗ “Fluorouracil, 5-FU, NSC-19893” NCT00002496 ↗ |
| Known as | NSC-3590 | “NSC-3590 5-FU Fluorouracil” NCT00002783 ↗ |
| Known as | pentafluorouracil | “pentafluorouracil (5-fluorouracil)” NCT05183958 ↗ |
| Known as | PI-FU | “Patients with clinically staged II or III esophageal adenocarcinoma received oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180...” PMID 22025151 ↗ Oct 2011 |
| Known as | Ribofluor | “Ribofluor” NCT00408694 ↗ |
| Known as | Ro-2-9757 | “Ro-2-9757” NCT00408694 ↗ |
| Known as | SinoFuan | “SinoFuan is a kind of Fluorouracil Implants for intraperitoneal chemotherapy during operation for treatment of gastric cancer.” NCT02269904 ↗ |
| Known as | Tolak | “5-fluorouracil 4% (Tolak)” NCT04875026 ↗ |
| Known as | Utoral | “5-fluorouracil 5% solution available as ampoules (Utoral®, EIMC United Pharmaceuticals, Egypt)” NCT05513924 ↗ |
| Action | Inhibit | “The use of 5-FU, an antimetabolite, has been shown to inhibit the proliferation of fibroblasts in tissue culture” NCT00000122 ↗ |
| Modality | Small molecule | “5-fluoro-2,4 (1H,3H)-pyrimidinedione” NCT03167177 ↗ |
| Route | Other | “intravaginal fluorouracil” NCT00000758 ↗ |